

EXHIBIT 7

Protected Information - Benjamin Lebwohl, M.D., M.S.

Page 358	Page 360
<p>1 Lebwohl-18, List of Search Terms, 2 was marked for identification.) 3 - - - 4 THE WITNESS: Thank you. 5 BY MR. MURPHY: 6 Q. And my question to you, Dr. 7 Lebwohl, is, if you were seeking to query 8 an adverse event database for suggestion 9 of sprue-like enteropathy and 10 olmesartan-associated enteropathy, would 11 you consider these search terms to be 12 adequate?</p> <p>13 MR. SLATER: Objection. 14 You can answer.</p> <p>15 THE WITNESS: I'm going to 16 look through the list and I'll ask 17 first for a clarification. Are 18 there items on here that I think 19 should be off or are there items 20 that are not on here that I think 21 should be on?</p> <p>22 MR. MURPHY: With regard to 23 the items that are there, you can 24 first tell me whether there are</p>	<p>1 question I would ask certainly as 2 a researcher is, well, do we want 3 to maximize sensitivity or 4 specificity, do we want to capture 5 as many as possible and then worry 6 about weeding out others later, or 7 do we really only want to identify 8 the tip of the iceberg at the 9 beginning? 10 So I think that's an 11 important question at the 12 foundation.</p> <p>13 BY MR. MURPHY: 14 Q. Assuming that we're beyond 15 tip of the iceberg. 16 A. If the question is do I want 17 to capture as many patients with 18 olmesartan enteropathy or this kind of 19 clinical phenotype as possible -- 20 Q. Yes. 21 A. -- then I would worry less 22 about being overly inclusive and add 23 others. I also would take issue with the 24 spelling and specific use of some of</p>
<p>1 any that you believe ought not be 2 on.</p> <p>3 THE WITNESS: In terms of 4 the FDA looking for adverse events 5 associated with drugs?</p> <p>6 MR. MURPHY: Well, not 7 necessarily FDA. I mean --</p> <p>8 THE WITNESS: Anyone.</p> <p>9 MR. MURPHY: -- a researcher 10 like yourself who might be looking 11 into this question.</p> <p>12 THE WITNESS: I think it 13 depends a bit on how sensitive 14 versus how specific one wants to 15 be. Is the question do you want 16 to cast the widest net possible so 17 that you can pick up early signals 18 or is the question that you want 19 to minimize noise and really only 20 focus on the signal, at which 21 point, we're sure to be missing 22 some patients with more atypical 23 or different kinds of signals?</p> <p>24 So I think the first</p>	<p>1 these terms and I can go over these with 2 you if you'd like. 3 Q. Okay. 4 A. So, for example, abnormal 5 feces, certainly a feature, not a 6 necessary feature, but certainly a 7 feature. Feces can be spelled in two 8 different ways. 9 Change of bowel habit is one 10 way to put it, but change in bowel habit 11 is another; and, also, habit is often 12 plural, so I'd probably use a combination 13 Boolean expression to allow for all of 14 those. 15 Coeliac disease is one of 16 these conditions that has a few different 17 names; and so this one condition, the one 18 spelling is appropriate, but I would 19 consider also searching for it without 20 the O in the word celiac. With the O is 21 more of a British spelling. 22 I'd also consider celiac 23 sprue. I'd also consider gluten 24 sensitive enteropathy and I would also</p>
Page 359	Page 361

Protected Information - Benjamin Lebwohl, M.D., M.S.

Page 362	Page 364
<p>1 consider nontropical sprue. These are 2 all terms that are interchangeable and 3 are used by different people to mean 4 really the same entity.</p> <p>5 Defecation urgency, I would 6 again consider spelling defecation 7 differently. The same goes for 8 diarrhea. There's an O in there and I 9 would consider taking it out as well.</p> <p>10 Enteritis, I don't take 11 issue with someone with olmesartan 12 enteropathy could have enteritis, but 13 what about enteropathy? I don't see it 14 here and I would certainly add it.</p> <p>15 Enterocolitis seems 16 appropriate given the enteropathy we know 17 is associated with olmesartan and also 18 the fact that many patients have 19 microscopic colitis.</p> <p>20 Fecal incontinence can be a 21 feature of olmesartan enteropathy, so I 22 would look for it with a mind that 23 there's more than one way to spell 24 fecal.</p>	<p>1 they might be misdiagnosed of having an 2 enteropathy due to diabetes as opposed to 3 olmesartan, so I would put it in there. 4 Protein-losing 5 gastroenteropathy is a feature, not 6 necessarily the only feature, and I would 7 include that, same goes for 8 gastrointestinal inflammation. And 9 intestinal mucosal atrophy seems fine, 10 but I would include some others. 11 Can I add what I think might 12 be helpful? 13 Q. Yeah, please do. 14 A. To start, microscopic 15 colitis, I think that's an important one 16 given that we know many patients with 17 olmesartan enteropathy share that 18 feature. And then I would use its 19 subtypes, lymphocytic colitis, 20 collagenous colitis. 21 I would also consider using 22 collagenous sprue given that the first 23 time olmesartan enteropathy was reported 24 in the literature was in the context of</p>
<p>1 Frequent bowel movements is 2 -- it is what it is. Gastrointestinal 3 seems appropriate. Malabsorption, given 4 the caveats we discussed above, is a term 5 that I'm not crazy about, but if I want 6 to cast a wide net and I don't want to 7 just try to find the tip of the iceberg, 8 I would keep it in.</p> <p>9 Intestinal villi atrophy, I 10 think, is not a great way to search. I 11 would prefer intestinal villous atrophy 12 or just villous atrophy. Villous can be 13 spelled in a couple of different ways, 14 V-I-L-L-U-S and V-I-L-L-O-U-S. Welcome 15 to my world. Right?</p> <p>16 Fecal volume increased, 17 again, I would respell fecal. 18 Gastrointestinal hypermotility is not 19 something that is commonly used, but it 20 seems appropriate.</p> <p>21 Diabetic enteropathy is 22 something that I would consider keeping 23 in simply because so many people who take 24 olmesartan happen to be diabetics and</p>	<p>1 that condition. 2 Let's see if there are 3 others that I can continue to look for. 4 I think vomiting is an important one, 5 nausea, vomiting, diarrhea. I would 6 certainly look for that. Many patients 7 have those symptoms. 8 I don't see abdominal pain. 9 I'm not sure why it was left off there, 10 but I would consider looking there. 11 I would look for 12 specifically refractory celiac disease 13 because so many patients with olmesartan 14 enteropathy are initially misdiagnosed as 15 having refractory celiac disease. 16 In that vein, I would 17 consider using those other terms that 18 have been used throughout the day, for 19 example, seronegative villous atrophy, 20 unclassified sprue, just sprue for short. 21 That would be another way to capture some 22 more. 23 I think dehydration would be 24 an appropriate thing to look for and I</p>

Protected Information - Benjamin Lebwohl, M.D., M.S.

Page 366	Page 368
<p>1 don't see it on this list. 2 I think if we want to cast a 3 net and try to find as many as we can, 4 those off the top of my head would be the 5 list of search terms I'd start out by 6 looking at, but it's very possible that 7 there are some that don't come readily to 8 mind that would also be manifestations, 9 features of olmesartan enteropathy that I 10 would include when doing my own search of 11 associations with olmesartan.</p> <p>12 MR. MURPHY: I thank you for 13 going through that and those are 14 my questions, Doctor. I thank you 15 for your time.</p> <p>16 THE WITNESS: Thank you.</p> <p>17 MR. SLATER: Okay. I just 18 need a couple minutes and then 19 we'll come back in.</p> <p>20 (A recess was taken from 21 6:17 p.m. to 6:32 p.m.)</p> <p>22 - - -</p> <p>23 EXAMINATION</p> <p>24 - - -</p>	<p>1 Talley, T-A-L-L-Y (sic), I guess it is, 2 about the -- what you cited there. 3 And if you could, can you 4 tell us what the quote is that you cite 5 in your report and then tell us what the 6 significance of that is from your 7 perspective and why you added that into 8 your report?</p> <p>9 A. Sure.</p> <p>10 Q. Or included that in your 11 report, I should say?</p> <p>12 A. Sure. This was a commentary 13 on the study by Basson and colleagues 14 that we discussed earlier today and it's 15 by Nicholas Talley, gastroenterologist, 16 and it's published in the Annals of 17 Internal Medicine.</p> <p>18 He writes, "The 19 well-conducted database study by Basson 20 and colleagues puts to bed any 21 controversy surrounding the association 22 between the ARB olmesartan and severe 23 intestinal enteropathy pathologically 24 resembling celiac disease."</p>
Page 367	Page 369
<p>1 BY MR. SLATER:</p> <p>2 Q. Doctor, you were asked 3 during your testimony about presentations 4 of olmesartan enteropathy less than one 5 year after initiating the drug versus 6 those after two years and were asked some 7 questions about that earlier in the 8 deposition.</p> <p>9 My question is this: Do you 10 have an opinion as to whether or not the 11 mechanism for why the person's symptoms 12 are being generated would be any 13 different where somebody's symptoms have 14 an onset in less than a year versus those 15 who are two or more years later?</p> <p>16 A. My opinion is that the 17 mechanisms should be the same. They are 18 the same regardless of the duration.</p> <p>19 Q. Looking at the last page of 20 your report, if you have that nearby --</p> <p>21 A. Here it is.</p> <p>22 Q. -- you were asked a little 23 bit about it and I think you wanted to 24 just express something about the quote to</p>	<p>1 He goes on to say, 2 "Evidence" surrounding "a causal relation 3 now includes the strength of association, 4 consistent findings, evidence of 5 improvement in most patients after 6 discontinuation, and relapse on drug 7 reintroduction" --</p> <p>8 Q. I just want to stop you.</p> <p>9 You said "evidence surrounding"? Does it 10 say "evidence supporting"?</p> <p>11 A. Forgive me. "Evidence 12 supporting a causal relation." Then it 13 goes on.</p> <p>14 Thank you.</p> <p>15 Q. And why is that of 16 significance to you? Why did you include 17 that in your report?</p> <p>18 A. I included it for a couple 19 of reasons: One is, I think it provides 20 a summation of the data that we have to 21 date because it is recent and it 22 incorporates some of the more recent data 23 we have.</p> <p>24 But I also include it</p>

Protected Information - Benjamin Lebwohl, M.D., M.S.

Page 370	Page 372
<p>1 because it's published in a high-impact 2 journal, by that, I mean high-reputation, 3 prestigious, often-cited journal, the 4 Annals of Internal Medicine, and the 5 language is clear that this issue has 6 really been laid to rest involving any 7 question about causality.</p> <p>8 Q. You were asked by counsel to 9 list those articles that state or -- and 10 you answered the question in the context 11 of stand for the proposition of the 12 causal relationship between olmesartan 13 and olmesartan enteropathy and you listed 14 a series of articles.</p> <p>15 If you were to go through 16 each article one by one, would you be 17 able to likely identify additional 18 articles?</p> <p>19 MR. MURPHY: Objection; 20 form.</p> <p>21 You may answer.</p> <p>22 THE WITNESS: I'm sure I 23 would identify additional articles 24 if I were to go through it again</p>	<p>1 the finding, do you have an opinion, and 2 if you can explain this, as to why that 3 is an important article in the overall 4 question of causation and how it fits 5 into the determination that you've given 6 of causation?</p> <p>7 A. A specific aspect of the --</p> <p>8 Q. You know what, I'm going to 9 withdraw that question, actually. I want 10 to ask you about something else, 11 actually. I want to ask you a completely 12 different question, actually.</p> <p>13 A. Okay.</p> <p>14 Q. I think you handled that one 15 for about an hour. I'm not going to go 16 back into it.</p> <p>17 Here's my question: You 18 were asked about the so-called hierarchy 19 of different types of studies, RCTs, all 20 those other type studies; and in the 21 context of olmesartan, in identifying and 22 studying the entity of olmesartan 23 enteropathy, can you just give us an 24 explanation of why it is or what your</p>
Page 371	Page 373
<p>1 that I didn't pick up the first 2 time.</p> <p>3 BY MR. SLATER:</p> <p>4 Q. In fact, on page 22 into 23, 5 you discuss an article by Schiepatti, 6 S-C-H-I-E-P-A-T-T-I, et al, and over to 7 page 23, you quote from that article: 8 "This study supports the causality of the 9 association between olmesartan and 10 enteropathy."</p> <p>11 Would that be an example of 12 an article you didn't list earlier, I 13 don't believe, that that would also stand 14 for the proposition? Is that an example 15 of that?</p> <p>16 MR. MURPHY: Objection to 17 form.</p> <p>18 THE WITNESS: That would be 19 another example.</p> <p>20 BY MR. SLATER:</p> <p>21 Q. You were asked about the 22 Greywoode article and I just want to be 23 very clear. Even though it did not 24 demonstrate statistical significance of</p>	<p>1 opinion is as to which studies have been 2 most helpful in understanding that entity 3 in the literature?</p> <p>4 MR. MURPHY: Objection to 5 form.</p> <p>6 You may answer.</p> <p>7 THE WITNESS: In fact, it's 8 the case reports with multiple 9 dechallenge and rechallenge in 10 multiple contexts from around the 11 world that are actually most 12 helpful.</p> <p>13 There are other study types 14 that we talked about earlier today 15 that have added to the impression, 16 but convincing case reports with 17 well-documented dechallenge and 18 rechallenge data can be the most 19 helpful, despite the fact that in 20 a generic pyramid of evidence, 21 case reports are on the bottom.</p> <p>22 In fact, RCTs are not well 23 suited to look at uncommon 24 long-term effects, both because</p>

Protected Information - Benjamin Lebwohl, M.D., M.S.

Page 374	Page 376
<p>1 the number of patients in an RCT, 2 for example, the ROADMAP study, is 3 not sufficiently high so as to 4 look for an uncommon effect, nor 5 do they follow patients long 6 enough to look for a long-term 7 adverse effect.</p> <p>8 And I should add that even 9 within the ROADMAP study, it 10 turned out that there were 11 patients who had olmesartan 12 enteropathy which was not noted by 13 the authors of that post hoc 14 analysis.</p> <p>15 BY MR. SLATER:</p> <p>16 Q. And when you say there were 17 patients that were noted that had that, 18 was that based on your review of internal 19 documents that were not publicly shared 20 with the medical community?</p> <p>21 A. Yes.</p> <p>22 MR. MURPHY: Objection to 23 form.</p> <p>24 BY MR. SLATER:</p>	<p>1 stopping medication. Do you see that? 2 A. Yes. 3 Q. There's a plus sign next to 4 two of the patients which means that 5 improvement was seen; correct? 6 A. Just two of the patients? 7 Q. Yeah, if you look down, if 8 you go down that column for the 9 olmesartan patients, there's a plus sign 10 for two of them. Do you see that? 11 A. Perhaps you can show me. 12 Q. (Indicating.) In that 13 column (Indicating). 14 A. Oh, the biopsy column. 15 Q. Yes. 16 A. Yes, I see plus signs in two 17 of those patients. 18 Q. That means there was 19 improvement seen. 20 A. That's right. 21 Q. Not applicable is indicated 22 for the rest. Does that mean there just 23 wasn't a biopsy to look at at the time 24 this was published?</p>
Page 375	Page 377
<p>1 Q. You were asked about the 2 variable rates of resolution and timing 3 of resolution, et cetera, of olmesartan 4 enteropathy; and in terms of your 5 opinion, why is that with regard to 6 olmesartan enteropathy?</p> <p>7 A. Why do I see that?</p> <p>8 Q. Yeah.</p> <p>9 A. It's analogous to variable 10 rates of healing we see in celiac disease 11 that include the individual's capacity to 12 heal that will vary from patient to 13 patient and we're likely seeing the same 14 phenomena, those patient-specific 15 variability, in olmesartan enteropathy.</p> <p>16 Q. Let's look at the DeGaetani 17 article for a moment.</p> <p>18 A. Sure. I got it.</p> <p>19 Q. Look, if you could, at table 20 3. I think that was the famous table 3 21 we've looked at a few times.</p> <p>22 A. I see it.</p> <p>23 Q. If we look at table 3, there 24 is a column for biopsy improvement after</p>	<p>1 A. That was my understanding, 2 that biopsies were not done. 3 Q. For those patients. Okay. 4 Now, with regard to that one 5 patient with the question mark in terms 6 of whether she had clinical improvement, 7 patient number 7 -- 8 A. Yes, I see that. 9 Q. -- during the course of 10 questioning by counsel, you had talked 11 about the fact that you thought it might 12 be that there was a lack of follow-up 13 data. 14 If you look at the 15 discussion section, below the discussion 16 at the bottom of the middle column, 17 there's a sentence that says, "Upon 18 discontinuation of this medication, all 19 15 patients on whom we had follow-up data 20 improved symptomatically, no longer 21 requiring immunosuppressive therapy if 22 they had previously been on it," et 23 cetera. 24 A. I see that.</p>

Protected Information - Benjamin Lebwohl, M.D., M.S.

Page 378	Page 380
<p>1 Q. So does that confirm for you 2 that there was a lack of follow-up data 3 on that one patient? 4 A. Correct. 5 Q. With regard to the Bradford 6 Hill criteria, did you consider the nine 7 different criteria as you evaluated the 8 evidence that was available to you in 9 forming your opinions in this case? 10 A. I considered those criteria 11 when I was evaluating the evidence. 12 Q. Even though you may not have 13 specifically named a few of them, it's 14 your testimony you did consider the 15 entire criteria? 16 A. Correct. 17 Q. And I think you mentioned a 18 few of the criteria during the course of 19 your testimony, like cessation of 20 exposure and others, those were criteria 21 you were aware of and applied? 22 A. Yes. 23 Q. In the Greywoode article, 24 there is a statement in the article</p>	<p>1 community rely on the information 2 companies provide regarding the risks, 3 for example, of medications that they 4 sell? 5 A. We do. 6 Q. And to the extent the 7 company has information internally about 8 risks, do you and other doctors expect 9 that that internal information is being 10 shared with you and others in the medical 11 community so you will have that in 12 treating and diagnosing patients? 13 A. Yes. 14 MR. MURPHY: Objection to 15 the form; lack of foundation. 16 THE WITNESS: Yes. 17 BY MR. SLATER: 18 Q. With regard to the internal 19 documents that you saw from Daiichi and 20 the deposition testimony you saw 21 regarding the adverse events they were 22 aware of and the internal discussions 23 about them, what was your reaction to 24 that when you saw that?</p>
<p>1 suggesting that milder presentations are 2 unlikely at that time. That's part of 3 the conclusion in the abstract? 4 A. Yes, it is. 5 Q. What's your opinion now at 6 this time and at the time you wrote your 7 report in this case as to whether it is 8 likely or unlikely that there are milder 9 presentations of olmesartan enteropathy? 10 MR. MURPHY: Objection; 11 form. 12 You may answer. 13 THE WITNESS: I believe that 14 milder presentations are, in fact, 15 likely. 16 BY MR. SLATER: 17 Q. Is that in part based upon 18 review of the literature and the case 19 reports that have been coming out even up 20 till very recent? 21 A. Correct. 22 Q. You were asked about 23 internal company documents. And do you 24 and other physicians in the medical</p>	<p>1 MR. MURPHY: Objection; 2 form. 3 THE WITNESS: Particularly 4 when I looked at the dates, I was 5 stunned by the dates, in that they 6 happened so far before the general 7 medical community was first 8 apprised of this condition. And I 9 would have loved to know about 10 those cases at the time that they 11 happened, well before the first 12 publications. 13 I think that my patients 14 would have wanted to and I think 15 that my group, the physicians in 16 the biomedical community, would 17 have wanted that information at 18 that time. 19 BY MR. SLATER: 20 Q. And why is that? 21 A. Given the morbidity that we 22 see in olmesartan enteropathy, the 23 suffering, the diagnostic travails that 24 many people have, the misdiagnosis,</p>
	Page 381

Protected Information - Benjamin Lebwohl, M.D., M.S.

Page 382	Page 384
<p>1 there's hospitalizations and sometimes 2 even worse, if we had known about this 3 entity well before 2012, we could have 4 prevented a good amount of suffering. 5 Q. And you've seen the adverse 6 event reports and you were asked some 7 questions about them today. Even if 8 Daiichi had just shared information about 9 these symptoms that they were seeing and 10 the syndrome that they were seeing, even 11 if they didn't know what the name of it 12 was and just told doctors, we're seeing 13 multiple patients with these clinical 14 pictures, would that have been helpful to 15 you and of interest to you and other 16 physicians in your field?</p> <p>17 MR. MURPHY: Objection to 18 form; lack of foundation.</p> <p>19 THE WITNESS: For sure.</p> <p>20 BY MR. SLATER:</p> <p>21 Q. And is that for the same 22 reasons you just stated?</p> <p>23 A. Yes. It also would have 24 helped our research efforts to better</p>	<p>1 nice weekend. 2 THE WITNESS: Thank you, 3 everybody. 4 (Witness excused.) 5 (Deposition concluded at 6 approximately 6:47 p.m.)</p> <p>7</p> <p>8</p> <p>9</p> <p>10</p> <p>11</p> <p>12</p> <p>13</p> <p>14</p> <p>15</p> <p>16</p> <p>17</p> <p>18</p> <p>19</p> <p>20</p> <p>21</p> <p>22</p> <p>23</p> <p>24</p>
Page 383	Page 385
<p>1 understand this condition.</p> <p>2 Q. You were asked at the end of 3 the deposition about search terms. And 4 in the interest of time, I'm just going 5 to ask you if the following terms would 6 also fall into the category of those you 7 would want to include if you were going 8 to cast this wide net to catch relevant 9 reports in the literature.</p> <p>10 And in the interest of time, 11 I'm going to list them: sprue-like 12 symptoms, chronic diarrhea, abnormal loss 13 of weight, weight decreased, underweight, 14 anemia, renal insufficiency, renal 15 failure, and steatorrhea, would those be 16 helpful terms as well?</p> <p>17 A. Yes.</p> <p>18 MR. SLATER: I have no other 19 questions.</p> <p>20 MR. MURPHY: I guess we're 21 done subject to resolution of our 22 request for the patient data that 23 I made earlier on the record.</p> <p>24 MR. SLATER: Everyone have a</p>	<p>1</p> <p>2 CERTIFICATE</p> <p>3</p> <p>4</p> <p>5 I HEREBY CERTIFY that the 6 witness was duly sworn by me and that the 7 deposition is a true record of the 8 testimony given by the witness.</p> <p>9 It was requested before 10 completion of the deposition that the 11 witness, BENJAMIN LEBWOHL, M.D., M.S., 12 have the opportunity to read and sign the 13 deposition transcript.</p> <p>14 KIMBERLY A. CAHILL, a 15 Federally Approved Registered 16 Merit Reporter and Notary Public 17 Dated: February 13, 2017</p> <p>18 (The foregoing certification 19 of this transcript does not apply to any 20 reproduction of the same by any means, 21 unless under the direct control and/or 22 supervision of the certifying reporter.)</p> <p>23</p> <p>24</p>

Protected Information - Benjamin Lebwohl, M.D., M.S.

Page 386

1 LAWYER'S NOTES

2 PAGE LINE

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

Protected Information - Benjamin Lebwohl, M.D., M.S.

<u>WORD</u>	318:6 385:15	208:24 209:20	43:14 44:12, 15, 18 84:8, 14	31 6:18 335:12 347:3, 10
<u>INDEX</u>	130 7:6 346:4	210:6 274:10, 14 276:17	335:12	
<0>	138:6 155:15	2:20 199:13	2017 1:7	32 306:21, 22
0.14 158:21	320:11 337:9	2:33 199:13	97:23 385:15	307:19, 23
003790 340:18	14th 332:4	20 222:2, 16, 19, 24 273:1, 3	20-pound	308:24 309:8
05 6:22 7:3	339:16 340:23	274:13, 18	319:13	320 6:12
160:7 230:12	15 4:21 6:8,	275:13, 21	21 7:3 86:16	325 322:11
340:2 346:1	12 28:10	277:15 311:3	346:1	33 309:9
07068 2:4	218:13 307:9	320:21	212 2:9	319:2, 3
07932 2:18	320:3 335:8, 18 345:16	377:19	215 2:14	335 6:16
<1>	377:19	200 5:12	22 200:7	339 6:19
1 11:3, 8 35:3	15-2606 1:6	2000 2:13	371:4	34 4:21
92:21, 24	16 5:1, 1, 3	2005 339:16	228-9898 2:4	334:11, 12
109:6 157:13	38:2, 2, 3	340:23 345:16	22nd 319:7	335:22 336:5, 6, 8, 11, 17, 18,
158:10, 18	200:7 201:15,	351:17, 18	23 5:1 38:2	21
159:2 220:8	23 204:21, 23	2006 309:24	40:8 42:17	3400 1:16 2:8
276:10	205:2, 18, 21	310:2, 4 311:2	84:3, 8, 13	346 7:3
1.99 158:16	206:9, 21	2007 319:7	92:21 93:1	347 6:14
1:11 140:6	209:1, 19	322:1	96:15 371:4, 7	320:5
10 1:7 6:8, 8, 12 8:11 256:7,	210:16, 17	2011 202:17,	23rd 39:4	35 5:1
17 274:12, 18	211:5 218:13	20 203:15	255 5:18	358 7:7
307:9, 9 320:3	220:9 243:17,	2012 18:6	26 4:21 34:12	35-year-old
10:36 56:7	17 277:24	23:6 178:13	262 5:22	344:3
10:46 56:7	278:1 339:21	196:3 197:19,	27 147:6, 8, 9	36 339:9, 11
100 243:9, 12, 13, 19, 24	340:13 343:5	22 214:15	271 6:4	340:15 345:5, 7 347:8
244:5, 5	160's 335:24	245:11 283:13	28 4:21	367 4:7
10022 2:9	164 335:24	313:14 348:11	224:21 241:3	36-year-old
102 238:24	17 5:1 35:23	355:23 382:3	250:24 254:10	
103 2:3	206:21 216:16,	2013 5:12	28th 39:8, 14	340:24
238:24	22 345:21	57:10 138:13	29 5:3 38:3	37 297:10, 11
105 269:1, 5	173 337:2, 9	161:13 200:21	39:4 40:9	300:1
11 5:1, 3 6:12	174 338:1	209:6 210:3	85:6	38 5:1
38:2, 3 42:18	178 5:10	214:11	2nd 2:3 332:2	
43:14 81:23,	18 5:1 38:2	2014 5:10, 22	<4>	
24 263:1	39:4 138:16	6:4 135:22	<3>	4 29:9 34:9,
320:3	155:17 357:21	140:22 178:24	3 28:7, 16	19 35:8 36:8,
12 271:3	18th 2:13	262:15 269:24	43:19 158:15	12, 15 81:14
276:13, 17	19 6:22 8:7	271:8	161:13 205:14,	180:10 275:13,
277:15 331:23	98:17 340:2	2015 5:18	17 210:4	21 297:12
12:25 140:6	19103 2:14	28:21 29:9, 15,	218:12 375:20,	4:34 297:7
12:30 139:24	198 8:11	21 30:6, 8	20, 23	4:44 297:7
1239 267:12	<2>	32:3 34:6	3:1 66:3	40 222:2
129 6:24	2 5:1 14:6, 18	53:12 84:13	3:32 254:7	420 180:10
340:3	35:3, 23 80:2,	6, 22 255:23	3:41 254:7	43 47:2
13 307:17, 17	22 81:7 89:9	310:3	30 37:19	44 37:17
308:5, 21	90:17, 23 91:1,	2016 6:18	161:18 162:13,	46 8:7
	10 206:9	28:2 37:10	14	
		40:10 42:18	307 6:8	<5>

Protected Information - Benjamin Lebwohl, M.D., M.S.

5 4:21, 21 28:10, 10 36:5, 8, 13 66:4 129:21 165:1, 2 177:13, 14 313:18 320:23 5.00 159:3 5:09 318:23 5:14 318:23 50 264:2 274:18 549-7000 2:19 58 345:16 58-year-old 347:1, 19 5th 28:21 97:23 < 6 > 6 37:23 38:20, 21 39:1 40:4 42:15 81:16 83:23 84:17 85:5 184:18 214:23 6:17 366:21 6:32 366:21 6:47 384:6 600 2:18 601 1:16 2:8 650 213:1, 9 < 7 > 7 6:22 38:9 88:24 92:5 158:9 161:8 199:18, 19 313:19 340:2 377:7 72 200:6 201:15 733 245:16 749 6:10 307:11 308:7, 10 79 159:2, 11 < 8 > 8 81:19 97:17 161:17 179:7 180:11 326:3	877.370.3377 1:22 88 5:5 < 9 > 9 4:5, 12 5:1, 1 7:3 35:23 38:2 134:5 276:1, 4 346:1 9:45 1:17 917.591.5672 1:22 95 158:14, 16 159:6, 8 973 2:4, 19 980-7400 2:9 988-2700 2:14 99 145:13 < A > a.m 1:17 56:7, 7 abated 319:19 abbreviated 257:2 abdominal 6:6 53:8 110:1 237:9, 10, 13 238:7 271:10 273:23 309:18 311:1, 13 312:11, 21 313:3, 5 314:5, 11, 17 315:10 365:8 ability 145:24 270:24 able 113:19 189:12 193:7, 11 199:3 231:14 242:22 313:20 338:10 370:17 abnormal 123:5 361:4 383:12 abnormalities 78:23 192:21 253:16, 20 290:3	abnormality 171:15 274:1 abouts 37:16 Abrams 93:19, 24 absence 60:4 111:3 170:3 245:2, 4 281:12 350:20 absolutely 280:21 absorb 119:6 absorption 259:18 Abstract 96:19, 22 97:3 113:13 267:14 270:16 273:20 302:10 379:3 abstractions 305:14 abundant 123:14 254:23 301:6 academia 270:22 accelerate 183:5 accelerated 342:18 accept 240:8 acceptance 335:3 accepted 108:18 160:5 262:8 access 16:9 329:24 accompanied 104:9 accompanies 86:9 Accompanying 11:10 account 94:15 100:17 243:2 294:22 accurate 22:11 274:7 314:16	accurately 15:23 156:12 196:13 264:14 297:23 accusing 161:20 achieve 160:8, 18 294:2 achieved 159:21 acid 265:17, 18 acknowledge 13:20 111:15 147:19 158:7 acknowledged 112:9 acknowledging 243:3 acknowledgments 336:24 acknowledgments 335:2 acquainted 59:16 acronym 231:2 234:5 action 49:4, 20 50:11, 15 51:14, 23 53:1, 19 56:10 57:14 activation 259:12 active 192:1 234:1 activities 43:9, 12 activity 259:11 actual 36:21 162:9 269:17 278:13 acute 66:24 171:1 acutely 126:12 327:3 ADAM 2:3 27:13 82:9 105:15 131:10 235:9 add 56:8 60:1 113:15	157:13 196:4 229:23 259:9 269:15 360:22 362:14 364:11 374:8 added 368:7 373:15 addendum 35:11 36:6, 18 addition 12:11 additional 33:19 88:6 112:13 161:11 321:24 370:17, 23 address 49:20 63:16 88:9, 11 114:6 224:23 226:11, 12 227:6 addressed 44:3 51:15, 17 52:23 57:13 63:2 addresses 53:18 63:10 addressing 28:4 50:10 51:13, 23 51:13, 23 292:11 297:14 299:19 adequate 358:12 adequately 230:18 233:24 adjusted 325:15 administrative 229:15 admit 163:8 adulthood 68:7 168:22 adults 222:14 223:5 advance 248:17 Adverse 6:21 58:18 66:23 148:18 149:13, 15 151:20 230:7, 17
--	--	---	--	---

Protected Information - Benjamin Lebwohl, M.D., M.S.

231:6, 12, 17	308:9 323:19	ambiguity	Annals 107:16	answered 44:7
233:4, 13	332:12	249:24	138:12 368:16	45:3 49:23
240:20 241:7	agreed 27:10	American 57:9	370:4	52:4 55:12
268:5, 16	233:12 334:20	amount 21:4	announcement	88:2 118:12
279:20 283:3	351:23	60:5 126:9	161:12 162:10	160:11, 13
286:18 303:4,	agreed-upon	223:10 259:13	Annual 96:18	172:16 205:1
11 304:8, 10,	125:14	269:16 382:4	Answer 8:5	233:8 241:24
17 306:4	agreement	Amy 3:2	10:8 13:19	253:10 296:9
334:19 337:17	125:5	analogies	16:6 20:4	342:20 370:10
339:15 340:1,	Ah 303:24	20:15	26:13 29:17	answering
22 345:14	ahead 26:4	analogizing	30:22 31:10	15:23 46:21
354:6, 13, 15,	38:22 94:20	122:14	36:11 45:4	108:3
24 355:14, 18	108:5 137:9	analogous	46:6, 19 47:16	antiarrhythmic
356:16, 17	259:2 292:18	67:21 103:14	48:4, 16 49:24	327:2, 4
358:8 359:4	325:12 353:15	121:21 176:14	52:9 56:9	anticipated
374:7 380:21	akin 261:15	291:7 296:16	57:18 63:6	284:12
382:5	al 5:17, 21	375:9	70:9 77:9	antihypertensive
advice 29:19	6:8 18:1	analogy 226:3,	87:24 88:3	191:14
30:1 33:7	110:15 115:22,	9	89:21 90:5, 22	Antihypertensives
63:23	24 201:1	analogy's	92:14 97:12	5:23
advised 16:8	256:2 271:13	290:5	106:22, 24	140:19 262:17
114:21 191:12	287:10 371:6	analyses 62:10	124:10 139:17,	apart 115:10
192:7	alarming	analysis 157:2	18 147:23	141:24
AERs 240:21	229:19	158:12 201:10	150:1 152:20	apologies
241:18 242:2	Al-Bawardy	224:16 225:6,	160:22 161:1	131:2 172:6
affect 127:16	97:16	18 231:21	172:14 173:2,	apologize
affirmatively	Alimentary	232:14 238:23	5, 18 174:6	117:14 120:1
47:21	135:16, 21	239:21 262:3	181:14 182:1	apparent
affirmed 9:8	allegation	353:20 374:14	190:11 192:3	169:4
affordable	23:23	analyze 240:15	193:13 194:11	appear 66:22
151:16	alleged 23:18	analyzing	203:4 207:4, 8,	67:3 127:22
African-American	25:15	247:20	17 208:7, 17	253:19 259:5
344:15	Allen 80:19	anecdotal	215:7 216:6	APPEARANCE
afternoon	84:4 323:15	284:13, 14	217:20 221:11	S 2:1
173:3	332:13	285:18, 20, 22	226:15 227:13	appeared
age 269:21	allergic 67:1	anecdotally	231:9, 14, 19	216:12 304:2
agent 143:1, 7	allow 65:20	284:1	234:9 235:6	326:4
149:12 167:14	288:20 296:5	anemia 119:9	236:4, 12	appears 34:20
176:22	361:13	121:3 383:14	240:12 249:14	121:9 122:7
agents 258:24	allowed 49:14	angiotensin	250:1 282:12	128:21 178:16
260:2	allows 69:3	6:7 53:10	287:3 289:5	220:12 223:1
aggregate	allusion 79:8	54:1 96:15	291:13 292:4	224:5 246:20
47:5 60:12, 17,	alternate	109:2, 14	294:10 296:11	256:23 260:16
22 184:6	257:15	110:3 153:11	302:8 310:12	280:9 288:12
aggregate,	alternative	237:14 251:9	313:16 314:10	313:6 331:15,
60:15	79:12 317:23	258:5 271:12	324:21 331:7	22
ago 24:20	318:4 326:9	angstrom	346:10 348:4	apples 247:6
60:10 303:3	334:8 344:6	109:21	350:5 357:12	applicability
agree 29:11	alternatives	animal 59:17,	358:14 370:21	261:22
179:22 225:3	317:20	19, 21, 23 60:1	373:6 379:12	
244:9 284:23	amazing 188:8	animals 59:15		

Protected Information - Benjamin Lebwohl, M.D., M.S.

applicable	architectural	133:1 136:8, 9	341:7 356:24	assume 21:11
149:11 150:14	122:8	137:3 138:24	asks 11:11, 19	95:6, 8, 12
376:21	architecture	140:9 151:24	aslater@mskf.n	114:11 250:4
applied	123:22	286:17 370:9,	et 2:5	292:7
333:21 354:21	area 72:24	14, 18, 23	aspect 223:23	assumed 78:10
378:21	87:3 141:1	ascertain	320:13 372:7	assuming
applies 287:3	areas 87:5	189:24	aspects 87:10	123:10 329:15,
apply 230:8	argue 59:18	ascertainties	90:1	18 337:3
385:18	133:9 154:9	203:23	assess 315:19	352:2 360:14
applying	185:14	aside 129:11	317:18	assumption
332:22 333:17	Arguellas-Gran	171:4 186:12	assessing	10:7
appreciate	de 110:4	asked 10:9	147:13 232:14	atrial 322:10
21:13 163:5	argumentative	18:14 32:8	assessment	327:6, 8
252:17 267:10	234:17, 19	33:2, 7, 16, 21,	Atrophy 5:14	
appreciated	235:1	24 34:2 43:13	316:13 323:20	51:9 57:1
24:11	arm 230:8, 10	44:7, 21 45:3	324:12	68:1, 3 109:16
apprised 381:8	239:23	47:18 49:23	assessments	119:20, 21
approach 37:4	Article 6:4	64:9 77:12	315:22 317:11	120:6, 8
approached	19:5, 7 20:19	88:1 102:24	assistance	121:18 122:2,
27:16 29:12,	21:12 53:17	118:7, 8	45:12, 21	6, 15, 19, 21
19 30:1, 10	98:18 106:10	130:12 136:9	Assistant 3:2	123:7 124:24
63:22 223:16	107:2, 10	141:2 151:23	Associated	125:3, 8, 15, 20
appropriate	109:7 110:21	155:20 160:10,	5:11, 20 41:24	133:24 134:7
21:19 22:1	111:21 112:10,	22 173:4, 6	42:1 75:3, 5	136:3 170:2, 4,
103:6 208:7	21 133:11	174:13 194:4	78:3 79:10	10, 15, 19, 22
265:9 277:10,	134:8, 13, 22	207:9, 13	96:17 100:11	171:3, 9, 18
11 302:20	135:3, 5 137:1,	223:17 241:23	110:11 111:4	200:7, 22
361:18 362:16	17 138:23	278:21 293:3	138:2 141:4	201:17 204:9
363:3, 20	143:3, 11, 13	295:16 296:9	153:12 156:1	205:8 214:8
365:24	145:2, 4	310:17 311:18	179:1 225:17	247:23 252:2,
appropriately	146:11 183:8	353:22 367:2,	232:4 238:22	5, 23 255:12
290:11	204:23 232:1	6, 22 370:8	253:3 257:18	350:21 363:9,
Approved	263:2, 7	371:21 372:18	267:19, 22	11, 12 364:9
1:18 301:3	267:12 271:8	375:1 379:22	268:4 322:16	365:19
385:14	305:22 370:16	382:6 383:2	323:2, 5	atrophy, 93:22
approximately	371:5, 7, 12, 22	asking 10:10	324:16 359:5	attached 15:16
296:1 384:6	372:3 375:17	24:4 32:13	362:17	Attaching
April 29:14,	378:23, 24	63:22 66:7	association	6:22 7:4
21 196:3	articles 21:8, 9,	83:5 98:8	111:6 114:16	340:2 346:3
197:19, 22	14 52:22	107:9 108:1	115:7, 12	attack 101:7,
214:14	59:13 63:1	124:2 132:24	129:5 158:20	8, 10
apriori 248:3	90:17 91:13	150:24 170:14	159:9 160:2	attempted
ARB 258:4, 4,	92:24 93:1, 15	173:9 175:8	161:1 227:6,	291:24
11, 14 259:14	95:20 99:18	204:7 217:21	12, 17 228:2, 9	attempting
273:14, 16	103:7, 11	219:5 233:6	229:6 237:24	317:18 342:1
275:7, 9, 24	105:6, 10	238:2 253:7	238:19 264:19	attention 47:1
276:8, 13, 18	107:12, 23	255:17 258:21	269:4 284:3	79:16 114:22
277:8, 16	108:7 112:19	268:15 277:21	368:21 369:3	137:8 165:14
368:22	113:1, 10, 20	291:2 295:13	371:9	166:5 205:13
ARBs 229:16	130:2, 10, 20	300:8 310:15	associations	212:24 224:21
267:18	131:4 132:14		157:4 366:11	254:10 274:10

Protected Information - Benjamin Lebwohl, M.D., M.S.

319:2 334:10	355:24 378:21	265:11 269:4, 18 279:4	believe 12:8 14:3 19:13 21:7 30:5 35:10 37:9, 14 42:7 43:16, 22	320:22 326:2 332:1, 8 341:2, 20, 24 345:17 351:12, 18, 22
attestations	awareness	282:16 288:23	BENJAMIN	
25:3	356:15	306:7 316:21	1:15 4:5, 14, 19, 23 5:8 9:4, 7 14:11 15:4	
attorney 9:17 13:15 24:24	axes 100:19 253:13, 20	334:18 343:22	34:13 88:18	
30:9	Aziz 133:4	374:18 379:17	89:2 385:8	
attorneys	153:18 155:19	baseline 277:9	best 24:19	
26:11	Azor 191:21,	basic 261:19	30:4, 11 32:2	
attribute	22	basically	33:6 37:19, 21	
201:11 324:5	< B >	187:24 190:16	61:17 197:21	
attributed	B-12 282:7	basis 50:5	203:24 309:3	
200:8 201:6	back 19:15	55:15 298:10	better 79:14	
203:2 205:2	35:4 36:24	baskets 95:5,	144:1 167:16, 22 171:3	
atypical	42:5 48:20	14	175:18 185:23	
359:22	54:10 55:6	Basson 75:17	186:21 187:5, 11 195:2, 8, 14	
author 20:24	66:12 70:14	112:14 114:5, 13, 14 115:16,	197:5 202:7	
57:5 120:15	86:13 90:5	21, 24 132:1, 3	221:23 236:18	
152:13 153:6	94:1 98:21	155:5, 6 227:7,	246:18, 23, 23	
236:22 237:2, 17	106:6 113:2	191:20 196:3	247:8, 10	
authored	118:10 139:15	197:18 204:15,	248:5, 9, 10	
237:5	152:5 169:1	19	285:8, 15	
authors 78:13, 24 113:4	171:21 173:3, 13 184:18	Bates 347:3	290:21 291:19	
146:22 147:3	189:11 193:4	bathing 258:23	294:1 325:22	
180:4 221:6	194:21 195:11,	bear 40:14	338:19 382:24	
261:1 283:18	17 197:5	177:12 216:18	beyond 46:8	
286:1 374:13	199:14 208:20	becoming	51:4 72:7	
author's 57:6	212:22 215:17	132:7	176:20 182:9	
autoimmunity	249:18 254:10	bed 368:20	199:20 261:20	
78:20	277:23 292:10	beg 104:18	268:13 360:14	
available	303:8 311:23	began 30:18	Bhagat 110:4	
91:18 116:1	316:23 318:17	31:17 32:3	B-H-A-G-A-T	
134:16 151:21	321:21 324:14	33:19 37:7	110:5	
209:11 260:17	339:3 351:18,	42:21 312:16	bias 149:7	
305:19 316:21	23 352:9	beginning	BIDDLE 2:12, 17	
317:15 378:8	366:19 372:16	1:17 56:22	big 95:5	
Avenue 1:16	background	67:8 114:12	biggest 277:2	
2:8	90:2, 12 95:5,	281:6 309:18	bill 43:15	
aware 21:1	10 338:8	360:9	billed 40:19	
61:1, 3 63:17	bad 126:15	begins 165:6	41:8, 10	
82:7 93:23	292:17	199:23 278:5	bills 85:18	
94:23 95:15, 16 97:20	barely 157:17	behalf 23:12	binder 12:2, 5, 12 15:12 16:1,	
98:19 99:3, 8	barrier 69:3	32:5	2, 3 17:6, 11, 16 19:16	
137:4 170:20	based 52:12	behold 247:21		
221:16 228:22	117:11, 16, 19	beings 60:6		
298:18 299:2	122:13 128:21	259:17		
300:20, 22	137:17 165:12	belief 211:11		
324:17 354:2	168:22 184:9	222:1 240:14		
	203:22 217:1	22 196:11, 23		
		198:4 216:12		

Protected Information - Benjamin Lebwohl, M.D., M.S.

20:17 21:14	blockers ,	breakdown	285:16 318:16	74:18 75:11
56:19 137:16	53:10 110:3	69:2	327:24	77:18 79:2
bioequivalence	blood 191:13, 17 285:11, 12	breeze 196:8	called 35:8	94:22 100:23
258:15	body 39:17 103:3	BRENNAN	47:12 78:20	101:16 107:7
biologic 51:6 67:23	bone 169:9	2:17	91:11 95:7	110:9, 15, 16
biological 49:7 51:10 52:17	Boolean	brief 25:3	100:10 295:14	112:13 122:5,
227:3 254:14	361:13	82:20 85:2	Campus 2:18	24 123:19
255:1, 11	borne 120:8	297:3, 5	cancer 26:21, 24 261:12, 20	128:5, 7, 23
256:10, 12	122:7, 13	bring 11:11, 20, 24 90:11	264:4	129:7 133:19, 20 141:10
biologist 59:3	127:8 349:13	91:22	cancer-derived	142:5, 8, 12, 14, 15 144:5
biology 72:8	bottom 81:6, 24 148:12	bringing 33:19	capacity 119:6	147:12 148:11,
biomedical	150:11 165:5	brings 9:18	356:13 375:11	12 149:17, 18
381:16	177:15 213:11, 14 274:16	24:8 27:6	capital 115:1	150:10, 10
biopsied	boundaries	British 361:21	Capsules	152:16, 21
121:22 122:17	144:2	broached	138:10	171:17 176:16,
biopsies 209:9, 10 210:7	bouts 128:20	197:6	capture	18 183:20
257:11 377:2	bowel 99:1, 5, 11 117:13	broad 52:17	150:19 264:12	185:16 186:2
biopsy 18:3	119:4 261:15	55:17 117:22	360:4, 17	193:3 208:24
120:12 121:5, 16 122:19	361:9, 10	144:9	broadly 53:23	209:5 216:22
123:12, 14	363:1	55:14, 16	captured	217:2 218:8
125:11 206:9	box 320:23	broke 141:1	228:14	222:6, 7
207:12 209:1, 20 210:5	326:3 330:22	brought 12:3	care 27:1	229:11 232:5
273:3 278:10	Bradford	15:12 40:14	171:5 202:24	239:23 240:20,
318:7, 13	224:16, 18, 24	112:9 281:18	205:10, 11	21 241:7, 18
343:6, 8, 15, 17, 18, 22 344:1	225:5, 9, 17, 21, 23 226:4, 6, 17, 19 227:1, 8	Budesonide	288:24	242:2, 14, 15,
375:24 376:14, 23	241:9, 12	138:10 183:2	cared 178:17	21, 21 243:7
bit 36:21	254:11 378:5	192:13, 14	298:14	247:11 248:11
112:20 127:7	branded 211:1	195:15, 17, 18	career 236:7	251:6, 16
211:4 212:10	Braunstein	244:1 245:19	careful 126:4	259:6 261:16
244:18 263:7	110:4 131:18	246:2	309:11	266:4, 5, 24
359:13 367:23	153:5, 9, 10	bulk 63:8	carefully	270:10, 12
black 280:7	263:3 271:5	Burbure	82:16 242:2	278:5 279:21,
344:4, 10, 17	break 56:3, 5	133:12 153:20	cares 291:15,	21 281:17
353:17	140:1, 4	B-U-R-B-U-R-E	16, 16	282:22 283:6
blank 37:8	156:13 194:17	133:13	caring 284:20	284:17 286:10,
blinded 97:19	198:19 199:10	<C>	Cartee 5:12	13 287:21
275:18	253:24 254:2	CACO 99:10	135:11 140:14,	288:12, 17
Block 39:11	158:16 258:19	260:19, 21	16 156:15, 16	289:24 291:3
blocker 258:5	297:5 318:15, 18	Caco-2 260:21, 22 261:5, 7, 11	179:2, 9 180:3	304:16 314:2
blockers 6:8	198:19 199:10	262:5	220:20 221:6	315:24 316:4
54:1 96:16	253:24 254:2	Cahill 1:17	C-A-R-T-E-E	323:17, 18, 22
109:3, 14	297:5 318:15, 18	10:14 385:13	179:10	328:1 333:22
153:11 237:15	198:19 199:10	calculated	Cartee-Murray	343:19 349:14,
251:10 271:12	297:5 318:15, 18	158:16 258:19	179:9 184:3, 5	14 353:16
		call 119:15	case 13:1, 2	373:8, 16, 21
		189:11 193:4	23:10 25:19,	378:9 379:7,
			22 26:1, 19, 20	18
			36:9 39:11	Case-Control
			60:20 65:8, 21	6:2 109:17

Protected Information - Benjamin Lebwohl, M.D., M.S.

140:21 143:22	20 224:24	63:3, 12 69:18,	23 188:23	58:17 62:3
149:21 150:6,	297:22 300:6	20 77:8 78:22	189:3, 5, 7, 14,	72:11 73:16
18 151:3, 19	317:18 335:2,	103:9 107:24	16, 20, 23	89:24 97:2
152:3, 7 153:1,	4 336:24	108:8, 10, 15	190:2 196:14,	103:12 115:2
14, 16 154:19,	370:7 371:8	109:18 111:22	16 200:22	118:5, 24
24 155:7, 22	Causation	115:1 131:6	204:4, 5, 10	121:12 122:3
156:3, 15, 18	4:24 23:18	133:24 135:24	210:12, 20, 21	123:3 125:9
239:3 262:20	28:5 34:14	146:7, 15, 19,	211:7, 10, 12,	134:20 156:22
266:7, 13, 21	107:19 112:22	23 147:4	19, 21, 24	164:5 166:3
cases 33:24	115:8 130:10	152:1 157:1	212:5 228:19	170:24 177:1
43:5, 23, 24	132:21 133:7,	170:17 338:11	229:1, 3, 14	179:20 185:13
51:7, 9 72:12	10 139:3	causing 65:12,	248:7 257:19	188:24 204:18
137:11 143:17	140:10, 11	18 142:4	266:18 290:6,	223:14 244:4
169:18 171:1	142:24 163:16	144:8, 17	11 291:3	279:20 289:9,
172:17 195:8	316:12 317:11	166:22 216:12	296:17 343:19,	14 291:3
206:4 220:9	372:4, 6	222:8 332:24	20, 21, 24	300:24 303:8
222:10 230:12	causation's	334:21 337:14	344:4, 7, 11, 14,	304:16 315:16
264:21, 24	143:5	351:19	17 353:1, 4, 17,	331:8 333:21
265:5 266:9,	cause 23:19	caution	20 354:1	344:13 349:13
23 289:2	62:1, 22 68:1,	110:10 126:17	356:6, 7	350:24 352:11
305:15 316:22	11 69:12	cautious	361:20, 22	355:1 360:1
338:6 345:3	71:19 74:15,	110:22, 23	365:12, 15	361:5, 6
353:20, 24	24 77:23	111:18 162:8	368:24 375:10	362:14 365:6
381:10	79:14 103:13	250:18 276:6	cell 99:1, 4	certainty 47:8
Caspard	108:19 109:6	caveat 110:19	260:19 261:1	166:14, 21
81:16 86:6	111:12 112:1,	134:14 202:22	cells 99:10	167:9 172:21
353:21	5, 17 115:13	caveats 363:4	260:20, 22	174:2, 22
cast 144:9	134:6 139:11	Celiac 5:14	261:5, 7, 7, 16,	211:15
359:16 363:6	141:14 143:8	18:3 20:14	18 262:1, 5	CERTIFICAT
366:2 383:8	149:12 165:20	67:20, 22 68:4,	cellular 51:4	E 385:2
cataloged	166:1 176:15	9 73:5, 10	52:14 55:14	certification
355:21	192:19 205:7	74:1, 4, 8, 13,	center 250:16	385:17
cataloguing	222:18 223:12	16, 20 75:6, 9,	certain 11:12,	CERTIFY
356:3	230:15 239:13,	14, 18, 22 76:4,	20 20:15	385:5
catch 383:8	14 251:14	10, 13 77:8, 20	43:24 45:7	certifying
category	257:15 304:2	78:3, 11, 16, 17,	65:15 67:20	385:21
113:22 383:6	316:6 318:4	20, 21 79:2, 11	80:15 95:19	cervical
caught 289:17	323:5, 23	93:20 116:5	99:1 163:14	261:17, 20
causal 47:5	324:1 326:9	120:18 121:1	164:6 178:13	cessation
60:12, 21	332:14 334:6	122:14, 16, 21	180:5 212:16	193:1 246:24
68:13 92:1	351:12	123:4, 9, 15	216:1 217:5	254:22 378:19
216:24 315:19	cause , 103:14	125:10 164:10,	232:15 241:6,	cetera 91:19
317:5, 24	caused 23:24	22 167:21	18 255:8	146:16 281:13
369:2, 12	166:10 201:8,	168:4, 5, 9, 12,	280:12 307:2	282:7 375:3
370:12	14, 18 251:20	17, 19, 23	353:1 354:8,	377:23
causality 61:4	252:5, 19	169:13, 15	14 357:8	chalk 98:11
68:14 87:20	253:6 288:21	170:3, 16	certainly	125:23
107:19 110:9,	315:14	176:14, 17	20:11 25:5	chance 107:6
17 111:14	causes 48:13	177:8, 17	29:19 30:16	111:7 199:2
114:6, 8, 12	53:20 57:21	178:7, 9, 15, 19,	40:16 49:5	change 79:6
146:10 147:14,	59:14 61:22	21 180:6, 20,	50:1, 22 55:18	126:11 167:15

Protected Information - Benjamin Lebwohl, M.D., M.S.

171:11 325:21	choice 240:1, 10	clarify 19:23 24:4 37:2	126:18 127:23 129:9, 18	codes 116:2 357:15, 18
328:12 361:9, 10	chose 129:8 246:13, 16 265:4	38:19 52:10 60:18 84:12 88:10 207:4	136:16 141:16, 18 165:13 167:12 175:14	Coeliac 361:15 cofactor 67:6, 12 69:7 72:6
changed 325:16	Chronic 5:23 128:11, 19, 23 136:15 137:21 140:19 238:1, 7, 20, 23	219:13 239:2 207:7 154:23	176:6, 9 177:20 183:3 187:1 205:21, 24 206:5 218:13 220:11	cofactors 69:14, 15 coherence 226:11, 16, 21 coherent 229:12 250:3
changes 49:7 50:7, 19, 21 51:10 53:23 54:2 117:12 288:20 290:23 296:6 329:13	239:11 262:17 383:12	classification 116:10 266:2	223:14 230:5 231:3 239:8 241:13 243:18 244:16, 24	cohort 149:21 150:5, 18 151:2, 12, 18
characteristics 100:6, 16 277:9 333:11	chronology 203:5	classified 203:10 233:10	246:21 250:12 252:21 253:8, 14 255:6	152:19 154:7 155:8 227:21, 23 242:24
characterizatio n 243:16	CIOMS 7:5 346:3	clear 17:7 32:18 51:21	257:5 280:8 288:23 289:2	colitis 362:19 364:15, 19, 20
characterize 111:17 119:18 201:22 227:22 244:5 245:1 246:14 276:10 279:24	circumscribed 317:1	circumspect 110:7, 19	290:2, 12, 19, 20, 24 291:17	collaborate 164:14
characterized 202:19 203:22 218:17 355:21	122:18 172:24 284:20 285:1	circumstances 148:21 178:12 179:23 235:5, 8 244:13	293:10 296:21 298:11, 13, 15	collaborated 164:11
characterizes 244:15	cite 21:3	cite 21:3	305:9, 10	collaboration 151:6
characterizing 281:7 317:24	251:2, 5, 15	clearly 43:10 68:10 169:6	306:5 323:10 325:7 333:12,	collaborations 164:23
charged 82:13	254:15, 19	176:16, 17	16 349:19	Collagenous 97:17 129:13
chart 134:9 185:8 186:6 209:17, 19, 23	255:15 256:12 278:10 334:24 335:22 336:4, 22 339:18	188:22 271:1 285:9 312:11 350:13	360:19 377:6 clinically 78:6 202:4 206:19 245:18 280:10	364:20, 22
charts 184:22 188:8 196:1, 6 197:20 198:13, 24 203:1	368:4	Clinic 140:22	291:9, 20	collated 304:19
349:1, 22	cited 94:12	180:6, 19	293:13	colleague 93:23
check 26:5 115:18 152:21 161:24 169:9 209:6 211:3 330:21 353:6	154:12 163:11 217:23 305:17	183:23 184:6, 14 185:17	clinicians 20:21	colleagues 56:16 65:22
checked 115:6	368:2	186:13 231:23	clinician's 211:11	66:1 75:17
checking 340:17	Civil 1:4	clinical 16:24	clinicopathologi c 58:9	93:19 94:8, 22
chemokines 51:4	Claiming 234:20	50:3, 17, 20 53:11 57:22	109:12 112:14	97:16 98:4, 18
Cherry 2:13	claims 229:15	58:11, 16 59:5	Clinic's 145:5	113:2 114:14
chest 101:9	claims-based 242:13	60:4 62:3 69:22 72:17	close 305:15 308:14 338:17	115:16 128:13
child 168:20	clarification 24:10 217:22	73:17 87:10 90:1 100:16,	closed 46:2 closely 75:23 82:16 211:4	133:5, 12
	358:17	20 101:12	232:18	135:13, 18
	clarifications 327:15	111:3 116:23 117:10, 24	code 116:11	136:14, 20
	clarifies 265:21	119:19 120:20	coded 326:3	137:10, 20
		121:1 123:20		138:1, 9
				140:18 144:4
				145:4 146:3
				155:3, 24
				184:22 187:23

Protected Information - Benjamin Lebwohl, M.D., M.S.

196:8, 22	coming	186:12	component	13 332:24
198:3 202:7	251:7 332:23	380:7	166:7 224:17	379:3
204:7 232:2	350:11 379:19	comparative	components	conclusions
248:2 268:8	comment	97:18	69:4	146:1
273:1 287:4	78:13 94:14	compare	comprised	concomitant
368:13, 20	207:10 329:23	222:2 248:15	40:5	313:2 343:20
collected	commentary	273:5 277:10	computer	concrete
200:5 204:11	103:18 368:12	compared	37:8	43:7
collection	commented	53:9 70:3	357:4	48:6 190:11
60:22	229:22	110:2 159:12	conceived	condition
colloquially	commenting	192:16 212:7	203:7	48:13 87:11
59:7 101:8	154:6	237:14 248:1	concentration	100:4 117:4
colon	common	257:6 258:3	258:17 260:4,	119:21 165:11,
26:21, 23 261:12	116:22 117:1,	263:15 271:11	7	12 169:17
264:3	2 118:3, 4, 17	273:1, 6	concentrations	177:5, 16
colonic	119:22 120:1	comparing	259:4, 21, 24	183:19 186:14,
262:1	121:19 124:3,	71:13 276:7	260:12	15, 16 201:18
colonoscopies	18 128:1	comparison	concern	202:16 240:17
26:22	141:3, 4 145:9,	260:1	concerned	245:1 251:20
colonoscopy	23 159:6	comparisons	230:4 304:3	252:8 253:1
157:17 263:15,	162:4 185:1	258:7, 9, 11	concerning	354:1 355:20
21, 24 264:2, 4,	210:21 239:13,	compatible	229:7	361:17 365:1
22 265:3, 8	18 241:16	121:12 289:9,	conclude	381:8 383:1
Columbia	263:13 265:15	12 350:24	107:23 111:24	conditions
235:23 236:7	267:6, 8 274:4	compelling	139:1 144:18	55:23 177:3
292:16	279:6 280:16	103:24 166:5	151:24 196:12	211:9 306:7
column	312:23 322:16,	285:19	concluded	361:16
206:15 213:8,	23 324:15, 18	complained	79:1, 4 101:23	conduct
12 277:3	325:2 327:23	141:12	141:13 142:3	58:23
375:24 376:8,	commonly	complaints	196:15 201:16,	286:2
13, 14 377:16	118:1 127:3	347:22 348:2	20 203:12	conducted
columns	192:13 280:13	complement	273:20 384:5	50:9, 12, 22
157:13 206:14,	317:17 363:19	212:3	concludes	51:13, 22
16, 17	communicated	complemented	111:21	52:24 53:19
combination	27:13	87:8	concluding	235:23 333:4
191:20 338:5	communication	complete	146:6 317:4	conferences
361:12	12:16 229:8	35:15 37:12	conclusion	58:9
come	communication	137:15	22:15 47:3	confidence
42:5 53:14	s 32:14 45:6	completed	60:8 87:14, 19	158:5, 14, 17
75:12 79:12	163:2 298:19	37:20 94:24	89:15, 16, 18	159:1, 7, 8
91:23 93:9	community	303:7	103:4, 8	confident
141:21, 23	64:24 113:17	completely	108:20 111:9	24:22 96:1
171:7 183:22	121:9 177:23	372:11	112:3, 12	212:4 270:12
185:18 204:10	374:20 380:1,	completeness	113:15 114:7	confidential
239:19 240:10	11 381:7, 16	177:21	129:4 131:5	299:9
299:21 306:11	companies	completion	135:23 138:23	confirm
339:3 366:7,	380:2	385:8	139:11 140:11	308:2
19	company	complication	144:21, 22, 22	346:17 348:15
comes	82:4	114:21	146:13, 18	378:1
145:17 190:19	298:1, 20	complies	156:23 185:11	confirmed
191:20 293:17	299:10, 16	216:17	186:8 267:11,	confirming
	301:2, 9 307:2			25:4

Protected Information - Benjamin Lebwohl, M.D., M.S.

confused	consultation	controls	155:6	160:23 162:17
336:17	14:2	263:16 264:21	164:1 169:21	378:4, 16 379:21
confusion	consulting	265:6, 19	171:14, 24	correctly
215:18	39:10	267:1 273:7,	174:10 178:7,	10:22 348:14
congruence	Contact	12, 24 274:20,	15 179:19	349:8
328:16	340:1	24 275:12, 22	183:12 185:12	correlate
congruent	contacted	276:12, 17	186:9 193:8	232:17 291:1
87:2	188:13 190:9	277:6	195:4 197:20	296:20
connection	196:17	controls, 274:5	200:13, 14	correlated
246:5 256:9	contemplating	controversy	205:8, 18, 23	159:4
consequence	57:20	368:21	206:11 209:22	correlates
158:23	contend	conversation	210:13 211:9	229:10 340:18
conservative	31:20	24:24 27:21	213:19 214:11	correlation
111:18	336:23	187:7 195:20	215:21 217:9	115:8 156:20
consider	Contents	215:2, 23	221:9 224:16	229:4
30:24	56:21, 23 80:5	conversations	225:1 227:9	correspond
111:11 118:24	105:9 305:4	32:20 33:14	228:19 231:7	164:13, 20
119:13 123:23	context	36:24	232:12 233:14	corresponds
294:20 351:7	262:7	convey	236:1 241:20	308:2
358:11 361:19,	290:10 301:12,	130:24	243:10, 14	corticosteroid
22, 23 362:1, 6,	19, 22 302:3,	60:20 61:24	244:7 247:4	183:3
9 363:22	14, 21 304:18	62:15 110:8	249:7 251:4,	corticosteroids
364:21 365:10,	305:23 306:3	123:19 168:2	21 252:19	247:9
17 378:6, 14	338:19 345:1	197:3 242:17	254:18 256:10	cost
considerable	364:24 370:10	273:16	258:4, 9 261:3,	41:24
278:6	372:21	copy	9 263:4, 5	Counsel
consideration	contexts	12:13	267:12, 21	3:2
225:5	373:10	105:8 179:8	271:21 272:22	11:5 12:17
considered	continue	Correct	274:6, 13, 22	13:10 14:2, 19,
128:10 194:5,	130:1 365:3	15:16, 17	275:15 276:3,	23 24:3 32:21
7 247:14	continued	26:18 29:6, 7,	15, 16, 23	46:21 198:10
281:11 334:9	326:2, 24	9, 10, 15 31:8	300:18 370:8	300:18 370:8
378:10	332:8	continuous	377:10	377:10
consistency	32:6 39:3, 5	32:6 39:3, 5	count	191:24
240:19 241:9,	294:15	40:5, 6, 9, 10	236:14 270:16,	23
12, 18	contrary	42:3, 4 47:10,	292:13 294:8	country
consistent	61:1	42:3, 4 47:10,	295:9, 15	189:21 264:6
369:4	108:14	11 53:21	297:24 300:18	couple
consistently	contrast	57:15 58:4	308:6, 8 309:7	9:21
356:4, 12	176:9	61:16, 18	313:14 314:7	30:6 104:6
constipation	control	65:10, 18	316:7, 9	114:18 140:8,
127:12, 18	152:16,	80:16, 17	319:13 321:21	23 141:2
128:3, 6, 20	21 154:22	81:17, 21 82:1,	322:2 323:24	307:4 309:16
278:8, 15, 20,	183:4 239:24	2 83:8 84:5,	324:8 328:5, 8	363:13 366:18
24 279:7, 7, 9	265:15 266:4	21, 22 85:6, 10,	329:16, 19	369:18
324:18	273:3, 15	21 86:1, 2, 4, 7	331:5 332:20	course
constitute	275:7, 9	89:13 90:20	337:1, 20	17:3, 5,
36:9	276:22 277:11	91:15 92:12	340:16 341:3,	5 27:22 64:2,
constitutes	385:20	95:23 100:14	20 342:2	13, 14, 21 65:5,
17:11 90:16	controlled	101:4 115:23	347:1, 19, 23	7, 9, 13, 15
constrained	148:10, 23	118:19 131:17	70:12 90:2	70:12 90:2
270:20	150:22 151:14	137:5 146:8, 9	348:2 355:5,	95:11 99:14
consult	256:19, 21	147:17 149:22	19 376:5	112:12 142:6
163:19	260:13 284:19,	159:16, 21	165:13 175:16,	

Protected Information - Benjamin Lebwohl, M.D., M.S.

20 194:12	190:21 201:21	296:22 316:18,	251:18	deficiencies
226:4 261:18	cultures 59:9	21, 23 317:1, 1,	deal 238:3	117:17
285:4 290:16	cumulative	15 324:11	dealing 217:23	deficiency
300:11 302:12	67:4 221:22	325:23 329:10	deals 232:11	119:9 121:3
325:16 329:20	curious 13:22	369:20, 22	dealt 303:21	define 175:6, 9
377:9 378:18	current 25:7	373:18 377:13,	death 173:4	316:3
COURT 1:1	239:7	19 378:2	decades 151:13	defined 117:8,
48:22 55:8	curse 95:7	383:22	December 23:6	22 124:21
66:14 70:17	99:12	database	deceptive	126:5 128:8
173:12 249:20	cut 208:7, 16	120:20, 22	233:19	168:13 221:23
312:7	cutaneous	354:3, 5, 7, 13,	dechallenge	278:6
covered 156:8	138:2	17 355:4, 8, 14,	142:16 165:15	definite
cradle 151:9	cutoff 160:5	18 356:16	166:9, 15	315:21 318:2
Crawford	175:20	357:9 358:8	167:1, 5, 11, 13,	definitely
81:20	cytokines 51:3	368:19	20 168:2	303:22
crazy 363:5		date 1:17	172:1, 12, 19	definition
created	< D >	28:1, 21 29:8	173:17, 21	227:24 246:16
301:13, 16, 17	Daiichi 2:15,	37:18, 20 53:4,	174:10, 17, 24	247:8 250:5
creation 302:4	20 3:3 9:17	12 84:6 97:23	175:2, 10, 17	266:8 295:10,
criteria 77:19,	82:3 136:7	196:3 202:11	203:5 217:2	21 298:7
22 78:4 128:9	297:18 300:21	302:16 309:23	242:19 254:24	definitions
184:12 224:18,	323:17 345:15	310:1, 4	283:15 288:5	101:15 125:4
24 225:9, 21	353:3 356:2	330:19 351:16	289:10 295:11	127:6 333:14
226:5, 6, 10, 17,	380:19 382:8	369:21	319:17 326:11	definitive
20 227:1	Daiichi-Sankyo	dated 39:3	329:9 373:9,	167:4, 17
241:12 246:9,	319:7 339:16	42:16, 16, 18	173:21 174:9,	
11 247:16	340:22	85:6 385:15	12, 14, 16, 17	
248:14 253:18	daily 294:19	dates 29:5	175:2 203:4	
254:11, 21	295:1 322:12	40:7 381:4, 5	dechallenge	definitively
257:14 313:23	damage 67:4	daunting 37:7	293:22 345:2	152:20 166:1,
333:16 378:6,	304:3	day 16:11	decided 77:5	9 172:9
7, 10, 15, 18, 20	Daniel 102:6	32:19 37:15,	decisions 298:4	240:13
criterion 78:5	dark 351:21	16 59:10, 10	deck 248:17	DeGaetani
183:16 225:12,	data 60:4, 6,	102:4 157:22	declared	5:17 56:15
14, 16, 22	23 61:1 113:5	176:6, 8 198:1	117:16	57:6 132:16
226:11 227:9	115:24 145:19	240:3 253:11	decreased	153:15 200:12,
240:18 241:9,	151:21 167:5	294:24 311:4	383:13	17, 24 204:1
20 245:14	173:22 174:24	365:18	deemed	205:13 218:4,
250:23 251:4	203:5 205:17	days 116:14	218:22 230:14	6, 12 243:11
254:14 255:1	209:18 210:5	170:1 251:23	deep 59:22	248:13 375:16
256:23 348:16	218:12 221:22	252:18 293:16,	deeply 59:16	degree 47:8
criticism 151:1	228:3, 5, 7, 15	19, 22 331:23	88:9	83:20 143:16
cropped 186:2	229:16 230:24	350:18	Defecation	166:13, 21
cross-sectional	231:1, 5	day's 39:20	362:5, 6	167:8 172:20
97:18	232:12, 14	day-to-day	defendant	174:1, 21
cry 325:6	233:9, 10, 12	58:11 298:10	23:13, 15	206:5 239:6
crypt 123:24	239:21 240:2,	305:10	Defendants	242:18 244:13
CSPV 334:18	15 242:13, 20	de 133:19	4:17 9:18	245:3 331:11
CSPV's 335:3	246:21 247:21	154:13	14:10 15:3	degrees 93:21
culprit 145:10	254:24 282:18	deafening	61:9, 14	122:8
	291:5 293:17			

Protected Information - Benjamin Lebwohl, M.D., M.S.

dehydration	41:12 77:14	describing	development	Diarrhea 5:24
51:8 284:7	80:15 81:20	184:10 263:11	72:5 150:20	51:8 119:1, 15
319:12 320:22	82:1 84:4, 11,	278:7	280:21	120:11 121:2
332:3 334:22	20 85:9, 21	DESCRIPTION	develops 70:4	126:21, 22
337:15 347:23	88:14 89:1	N 4:12 29:5	76:9	127:2, 6, 9
350:20, 24	91:14 96:24	129:19 211:5	diabetes 364:2	128:1, 11, 19,
365:23	101:22 102:3,	239:7 281:17	Diabetic	24 137:21
deliberate	5, 16, 18, 20, 21	320:19	363:21	140:20 143:22
283:15, 20	178:23 179:8	design 144:19	diabetics	144:8, 11, 17
deliberately	200:20 255:22	145:18 202:23	363:24	145:9 157:5
286:5	262:14 263:1,	266:19	diagnose	159:10 160:3
demarcated	9 271:7 307:8	designed	118:21 120:3	183:4 238:1, 8,
43:10	308:6, 12, 14	63:20 157:21	126:23 290:9	16, 17, 20, 23
demise 166:24	320:2, 12	231:11 233:23	306:6	239:11 262:18
173:16	335:1, 10, 12,	239:3 247:18	diagnosed	263:14 264:8,
demonstrate	19, 20, 21	designer 56:14	73:20 74:20	20 265:1, 2, 4,
335:2 371:24	336:18, 23	designing	117:3 119:23	10, 16 266:10,
demonstrated	339:23 345:24	63:23	165:12 168:17,	17, 24 267:19,
274:11 276:14	357:24 367:8	designs 239:20	19 169:13	23 268:23
277:17	380:20 383:3	desk 316:19	184:14 196:14	278:9, 16, 19
denied 61:12	384:5 385:6, 8,	325:3	248:6 343:22	279:6, 10, 14
denominator	9	desperate	diagnoses	280:14 312:15,
246:8	depositions	197:1	211:1 229:15	24 313:10, 11
denoted	61:10 82:11,	despite 323:13	diagnosing	314:6, 13, 18
218:15 220:7	12, 15 83:10,	342:4 373:19	306:9 380:12	315:9 319:12
density 169:9	14 85:3, 12	detail 93:11	diagnosis	320:21 325:5
deny 62:16	89:11 90:18	details 25:20	26:24 50:17	326:1, 3
denying 235:6	94:5 100:3	338:7	64:22 72:19	330:13 332:3,
337:13, 17	300:12 301:10	detect 233:24	73:8 78:22	7 334:22
dep 198:15	302:13, 14	270:8	100:17 120:18	337:15 341:1,
department	deps@golkow.c	detected	124:4 168:14	19 348:2, 7, 12,
58:24	om 1:23	158:19 270:3	172:21 180:16	13, 15, 18, 23
depend 36:20	depth 83:12,	determination	189:4, 6	349:3, 5, 12, 17
151:4	17, 19 88:11	324:9 338:11	210:12 212:20,	350:3, 7, 12
depending	123:24	372:5	21 214:11, 13	351:22 362:8
118:23 245:22	derivation	determine	228:13 306:13	365:5 383:12
266:19	261:12	17:9 33:1	315:13 316:9,	Diarrhea,
depends 96:9	derive 242:12	205:7 263:12	11, 15, 17	136:15
143:12, 12	derived 261:11	281:23 292:1	317:3, 13, 16	diarrheal
244:18 359:13	describe 25:24	316:6	318:3 332:23	111:10 288:21
deposed 23:4	129:9 283:13	determined	333:4, 13, 21	296:6
26:8 82:4	286:11, 14	143:7 202:12	334:2, 4	dictated
deposition 1:7	described	214:2	343:24 350:21	246:11
4:14, 20 6:18	55:19 133:19	develop 67:22	353:18 357:15,	dies 166:18
8:2 9:2, 3	188:14 211:6	69:8, 15 76:5	18	diet 78:15
11:3, 4 14:8,	217:2 247:20	developed	Diagnostic	168:21 180:22
13, 18 15:5	282:16, 24	96:20 97:3	5:15 57:3	197:7, 15
23:1, 3 25:1	283:7 296:23	253:18 340:24	78:1 200:23	211:14 212:7
26:9 28:9, 17	334:23 337:16	developing	257:17 381:23	281:2, 5, 10, 15
34:11, 20		68:19 97:5	diagrams	290:10 342:11
35:22 38:1		342:15	212:13	

Protected Information - Benjamin Lebwohl, M.D., M.S.

dieting	342:1, 4, 6, 9	219:17 224:20 235:8 274:9	220:21, 23 233:11 240:22	210:12, 20, 21 211:8, 10, 12, 20, 22 212:1, 5
differ	277:8	297:9 334:10	272:24 278:5	228:19 229:1,
difference	335:6	385:20	280:24 298:13	3, 14 245:5
247:2, 5	directing	319:1	305:21 363:4	248:7 257:19
266:12 291:8	Direction	8:5	368:14	266:18 290:7,
differences	directly	19:17, 22 20:7, 8 45:8 234:14	discusses	11 291:3
72:2, 9 259:1	276:7	306:19	discussing	296:18 342:11
273:22 276:9	disagree	243:23 316:16	43:23 50:15	343:19, 21, 21,
different	27:15	220:19 292:23	68:14 198:2	24 344:4, 7, 11, 14, 18 353:1, 4,
69:19	discharge	284:8	18 354:1, 5	18 354:1, 5
73:22 100:19	disclosed	22:6 43:5	356:6, 7, 10	208:19 217:15
117:9, 9	discontinuation	87:7 94:4	361:15 365:12,	221:16 230:23
125:12 126:1	78:6 183:17	207:24 213:3,	15 368:24	235:22 252:15
144:14 170:8	195:3 202:8	7 284:16	375:10	254:9 256:6
171:14 246:7,	246:2 281:22	307:19 377:15,	diseases	262:24 268:7
8 247:3 248:1,	282:1, 14	15	111:4	282:23 288:18
14 249:6	287:12, 17, 19	discussions	116:11 261:22	297:9 298:18
251:13 253:13	295:22 326:17	380:22	262:7 343:20	299:16 304:13
257:4 258:6	369:6 377:18	disease	dismiss	306:20 307:16
333:16 353:11	discontinue	18:3	285:18	308:20 310:9
359:23 361:8,	168:11 191:12	20:14 67:20,	disorders	317:9 319:1
16 362:3	192:8 201:24	22 68:4, 10	75:2, 5 78:2 79:10	320:10 321:21
363:13 367:13	discontinued	73:6, 11 74:1,	177:19 257:18	335:17 340:12
372:12, 19	186:22 187:6	4, 9, 14, 16, 21	disparaging	345:5 366:14
378:7	206:11 215:5	75:6, 9, 15, 18,	284:15	367:2
differential	216:3 217:9,	22 76:5, 10, 13	disparities	doctors
306:13 316:8,	18 218:10	77:8 78:4, 11,	18:2 120:18	73:14
10, 15, 17	282:6 295:8	17, 17, 21 79:2,	dispute	188:4 243:23
317:3, 13, 16	326:19, 22	11 93:20 99:1,	99:9 181:6, 7	380:8 382:12
318:3 332:23	328:5, 8	5, 11 116:6	disrespect	doctor's
333:4, 12, 18,	331:12 332:2	120:19 121:2,	164:12 193:12	13:23
20 334:1, 4	discontinuing	22 123:4, 9, 16	Document	5:5
351:5	209:2, 22	125:10 164:10,	13:7 14:18	13:7
differently	discovered	22 167:21	15:7, 10 29:4	15:7, 10
37:5 125:12	196:10	168:4, 5, 9, 12,	disseminated	29:4
245:3 362:7	201:13 203:11	18, 19, 23	230:19 352:11	80:23 85:8
difficult	246:5	169:13, 16	dissemination	88:15 89:3
10:14	discovering	170:3, 16	310:6, 7	233:1, 3, 6, 7
189:24 197:15	196:10	176:15, 17	dissolving	300:9 301:15,
298:17	discrete	177:8, 18	259:18	16 302:2, 4, 16
Dilemma	175:21	178:7, 9, 15, 19,	distinct	310:18 311:16
5:16	discuss	21 180:6, 20,	distortion	312:19 320:13
57:4 200:24	261:1 286:19	23 188:23	122:9	321:13, 19
diminish	295:7 340:14	189:3, 5, 7, 14,	distressing	328:3, 3, 10
149:7, 17	371:5	16, 20, 23	350:11	330:5, 10
dimly	discussed	190:2 196:14,	distributed	331:10 343:13
95:16	26:11 96:23	17 203:13	250:15	documented
dinner	163:7 184:2	204:4, 5, 10	DISTRICT	78:19 312:12
235:17	219:2, 8	149:19	1:1, 2	313:8
dire			disturbances	documenting
195:19			325:19	345:14
direct			diversion	
79:16			149:19	
129:20 147:7				
158:23 177:11				
205:12 212:24				

Protected Information - Benjamin Lebwohl, M.D., M.S.

Documents	<i>12, 17, 17, 22 88:5, 18 89:2, 12:7 16:15 84:24 91:18 95:17 136:7 297:13, 19 298:2, 6 299:8, 9, 11, 18, 21 300:3, 13, 15, 22 301:9, 13, 23 302:11 340:23 374:19 379:23 380:19</i>	<i>338:5 352:4 367:5 369:6 Drug-induced 135:12 136:15 137:20 154:18 247:22 drug-related 164:5, 9, 16, 24 184:21 185:15 187:7, 22 198:23 200:2 202:13, 15 204:1, 2 214:15, 19, 19 215:3, 13, 20, 20, 24 216:1 263:3, 3 271:4, 5, 20 324:5, 6 332:18 333:2, 24 349:2, 23 358:6 dramatic 187:1 197:3 289:3 draw 47:1 145:24 drawer 240:2 drawn-out 285:5</i>	<i>89:23 102:24 129:11 137:2 141:1 173:3, 4 178:11 179:11 203:16 219:8 239:2 250:7 253:10 260:18 263:7 278:21 294:13 296:23 313:24 367:7 368:14 371:12 373:14 383:23 earliest 313:21 due 37:16 50:4 71:4 73:9 109:1, 4 111:6 119:5 122:17, 20 177:19 195:9 228:23 247:23 252:23 283:16 285:9 364:2 duly 385:5 duodenal 18:2 120:12 273:3 278:10 Duodenitis 96:18 DRINKER 2:12, 17 drip 294:15 Drive 2:18 Drs 12:14 drug 12:15 23:18, 24 78:6 163:1 182:20, 21 221:8, 14 229:8 260:4 284:16 288:5, 7, 8, 10, 13, 19 292:11, 12, 15, 23, 24 293:9, 24 294:7, 18, 24 295:15 301:3 304:8, 11, 17 315:20 318:1 325:1 330:7, 24 331:4, 11, 15, 22 332:11</i>	<i>14, 16 EGDs 264:5 Eisenhower 2:3 either 30:14 35:11, 13 67:3 85:12 100:3 113:12 130:2 132:21 137:6 138:24 139:1 145:23 154:15 170:15 184:11 187:11 192:11, 24 195:16 32:3 34:6 196:6 209:10 218:20 230:13 237:23 238:3 239:23 243:5 245:1 246:22 251:24 easy 16:9 104:5 304:9, 12 eat 272:16 eating 189:9 197:16 290:8 editor 231:24 290:11 elicit 352:16 E-Mail 7:3 311:24 318:16 346:1 e-mails 30:13 embarking 293:1 emerging 230:1 244:24 emphasize 150:13 employ 355:3 employed 299:15 317:17 355:1 employees 298:20 employing 355:7 encapsulations 306:2 encounter 69:4 111:10 171:17</i>
------------------	---	---	--	--

Protected Information - Benjamin Lebwohl, M.D., M.S.

encountered	12 34:1 47:7	23 175:15	138:12 146:15	equal 259:24
108:11 300:10	48:14 49:9	176:19 177:22	154:21	260:11
encountering	50:17 53:21	178:6 179:1	entire 68:17	esophagogastro
128:14 244:24	54:7 55:22	180:18 183:23	321:18 327:12	duodenoscopy
encouragement	61:13, 22 62:2,	187:15 191:4	378:15	157:15
197:13	2, 5, 9, 13, 17,	203:3 210:24	entirely	especially 93:5
endeavor	23 63:3, 9, 13,	214:3, 17	187:11, 12	101:7 116:14
316:5	21 64:4, 7	216:24 220:9,	223:20 348:19	229:24 327:3
ended 142:19	65:1, 12, 18	16 221:19	entities 230:1	ESQUIRE 2:3,
189:6 196:16	67:14 68:19	222:9, 19, 22,	Entitled 5:5	7, 12, 17 3:2
197:16	69:9, 12, 18, 21	23, 24 223:3, 9,	88:15	essential
endoscope	70:2, 4 71:1, 8,	13, 16 224:4, 7,	entity 33:8	167:18 260:8
239:11	15, 20 72:18	9 228:11, 12,	61:5 72:17	essentially
Endoscopic	73:12 74:2, 7,	23 232:3, 18	73:3 101:12	62:16 224:15
6:1 140:21	9, 12, 24 76:6,	239:5 246:15	124:17 126:18	establish
262:19	8 77:24 87:5	251:14, 19, 23	190:22 252:21	165:19, 24
Endoscopy	100:5, 7, 8, 9,	252:9, 12, 18,	166:9, 13	166:9, 13
18:5 120:16,	10, 11, 12, 13,	20 253:3, 4, 5	172:9	172:9
20, 22, 24	24 101:17	254:17 256:1,	established	established
121:4, 14, 15	103:9 107:24	18 257:2, 4, 7,	75:1 77:24	75:1 77:24
122:1 123:6	108:9, 10, 16	15 262:4	92:2 142:24	92:2 142:24
239:19 264:11,	109:1, 18	268:3 269:3	226:21	143:6 146:11
14 265:12	110:11 111:5,	270:6 278:23	enumerated	217:1 257:16
267:24 269:20	22 112:2	279:4, 13, 18	82:17 90:15	258:15
endoscopy,	113:12 115:2	280:14, 18, 22	226:7	establishes
267:20	116:9, 12, 20,	287:6 289:1	enumerating	47:5 60:12
endpoints	21 117:7	296:17 297:14,	111:24	estimation
356:9	118:22 119:2,	22 299:19	enumeration	330:23
ends 114:14	23 120:5, 10	300:6 310:8	226:19	et 5:17, 21
engage 43:5,	121:13, 20	315:14 316:7	environmental	6:8 18:1
13 316:8, 10	122:24 123:21	323:6 325:21	65:17	91:19 110:15
engaged 23:12,	124:4, 20	332:16 333:1	epidemiologic	115:22, 24
14 27:8 33:3	126:24 127:4,	344:19 345:4	50:22 75:16	146:15 201:1
61:15 302:23	10 128:2, 15	348:21 350:15,	epidemiological	256:2 271:13
engagement	131:6 133:21	22 351:1, 7	281:13 282:7	281:13 282:7
31:17	135:12, 20	352:10 355:16,	50:13 58:23	287:10 371:6
engine 98:11	136:2, 21	17, 24 358:9,	59:6 87:10	375:3 377:22
ensuing 186:3	137:11 138:2	10 360:18	242:4	ethical 26:4
ensure 259:24	141:7 143:17	361:24 362:12,	epidemiologist	evaluate 18:3
entails 175:10	146:7, 20, 23	13, 16, 21	59:2	265:18
enter 355:7	147:4 150:20	363:21 364:2,	epidemiologists	evaluated
enteric 127:16	152:1 154:18	17, 23 365:14	151:7	214:16 378:7
Enteritis	156:1, 21	366:9 367:4	epidemiology	evaluates
362:10, 12	157:1, 6 162:6	368:23 370:13	17:1, 3 58:21,	233:21
Enterocolitis	165:20 166:2,	371:10 372:23	22 59:1 68:12	evaluating
362:15	11, 23 167:7	374:12 375:4,	92:3	148:17 378:11
enterocyte	168:13 169:7,	6, 15 379:9	epithelium	evaluation
259:15 260:5	18, 19, 23	381:22	127:15	78:1 79:9
Enteropathy	170:9 171:23	enteropathy,	Epocrates	144:10 145:8
5:11, 20 20:16,	172:11, 22	132:11 135:16	325:4	184:14 265:1,
22 31:1 33:9,	173:24 174:15,			2, 3

Protected Information - Benjamin Lebwohl, M.D., M.S.

Event 6:21 149:13 230:10 240:20 241:7 268:16 279:20 283:3 286:18 309:23 310:5 315:20 318:1 320:19 334:19 337:17 339:15 340:1, 22 345:14 354:6, 13, 15 355:14, 18 356:16, 17 358:8 382:6 events 148:18 149:15 230:7, 12, 18 231:6, 12, 17 233:13 303:11 322:8 354:24 359:4 380:21 eventually 96:19 everybody 384:3 evidence 47:4 60:11, 21 96:18 103:3 111:4 114:16 147:13, 14, 21 149:16 151:17 153:13 166:20 168:1 174:9 206:10 209:1, 21 227:16 251:3 256:11 279:3 318:7 329:7 343:6 369:2, 4, 9, 10, 11 373:20 378:8, 11 evidence-based 16:24 150:4 evidenced 180:21 evinced 218:13 325:24 evolved 27:22 exact 187:8 196:2 225:11 315:2 346:20	exactly 114:10 322:21 327:18 EXAMINATIO N 9:11 257:22 366:23 examine 238:16 examined 9:9 examining 316:20 example 17:2, 20, 21, 24 18:7 19:6, 13 20:13 22:10 25:3 53:3 69:1 72:9 83:20 91:24 93:6, 19 94:19 96:9, 14 97:22 98:5 103:17 112:11 119:1, 4 125:16, 17 126:6 143:14 157:12 167:19 168:17, 20 170:20 171:1, 8 211:16 223:18 226:3 227:11 230:6 242:11 243:11 245:16 254:23 280:19 283:10 285:6 295:17 304:19 325:2 333:8 339:19 345:10, 13 355:22, 23 356:2 361:4 365:19 371:11, 14, 19 374:2 380:3 examples 99:16 exceeded 222:9 exception 24:2 191:6 excerpt 335:19 336:3 Excerpts 6:16 335:11 338:16	exchange 338:15 excluded 245:17 exclusion 247:16 256:22 exclusively 169:24 excused 384:4 exemplify 345:4 exercise 113:1 126:16 exercising 333:18 exhaust 131:3 exhausted 97:14 exhaustive 225:15 254:20 Exhibit 6:10, 14, 24 7:5 9:2 11:2, 8 14:8, 18 28:7, 9, 16 34:11, 19 35:3, 3, 8, 22 36:5, 12, 13, 15 37:18 38:1, 9 39:1 40:4 42:15 43:19 80:2 83:23 84:17, 17 85:5 88:14, 24 89:9 90:16, 23 91:1, 10 92:5 161:8 178:23 179:7 200:20 255:22 256:7, 17 262:12, 14 263:1 271:7 307:8, 10, 17, 17 308:5, 5, 10, 21 318:6 320:2, 4, 11 335:10, 18 339:23 340:3, 9, 13 343:5 345:21, 24 346:4 357:21, 24	exhibited 274:18 276:18 exhibits 34:22 35:2 36:8 44:1 300:13 301:10 existed 95:15 existence 61:12 62:17 existing 33:17 exists 114:12 expect 380:8 expensive 64:1 experience 16:22, 23 72:11 73:4 90:1, 12 95:10 114:22 125:9 183:8 184:6 200:3 279:14 288:24 289:6 296:15 323:11 experienced 284:4 322:7 341:18 experiment 55:20 57:13, 23 226:23, 24 227:4 experimental 260:14 experimentatio n 53:18 experiments 50:10, 13, 23 51:13, 16, 22, 24 52:23 62:11 258:18 259:22 261:5, 20 expert 1:7 4:21 12:14 13:3 22:20, 23 23:2, 4, 22 25:17 27:8, 10, 17, 20 29:13 30:19, 24 31:7, 12, 19, 21 32:4 33:2 34:12 61:8 62:20 86:10 87:16	90:18 91:13 98:22 99:20 100:3 163:15 275:18 302:24 expertise 29:20 30:2 77:1 87:4 experts 20:21 163:20 explain 10:3 69:11 107:3, 5, 6 372:2 explained 103:1 255:7 explaining 235:5 explanation 10:17 74:10 79:13 112:7 127:13 216:10 338:2 372:24 explanations 334:8 344:6 explicating 225:21 explication 220:6 explicit 103:12 117:15 explicitly 84:23 93:10 94:1 132:22 258:1 327:9 334:3 explore 143:16 exposed 69:5 79:5 223:10 248:22, 23 249:3 266:14 276:23 277:16 281:1 exposure 67:10 114:18 145:22 158:3 229:9 254:22 267:5 280:4 378:20 expounded 219:18 express 270:24 367:24
--	--	---	---	---

Protected Information - Benjamin Lebwohl, M.D., M.S.

expression	216:1	126:22 128:1	field	62:20	172:2 189:18
132:10 361:13	failure	185:1 274:12	265:11	382:16	190:3 209:14
extensive	Fair	276:5 279:8,	fight	106:7	finishes
296:15	18:18, 21 21:4	10, 10, 15, 18,	figure	264:17,	firm
extensively	30:20 112:22	19 349:10	18	287:21	first
261:13 262:6	142:11 152:22	361:5, 6, 7	296:2		20:24 26:5
extent	188:19 208:10	362:21 364:5,	figured	190:14	27:12, 15 29:8,
86:23 87:21	305:24	6, 18	191:3	294:3	24 36:16
215:17 260:1	fairly	features	24:23		42:16, 17, 21,
291:23 303:7	24:22	50:18	filings	298:21	24 43:10 57:5
305:20 380:6	96:1 164:23	71:24 74:10	filled	68:17	65:21 66:17
extremely	349:20	100:20, 20, 21	final	37:14	68:5, 5 70:11,
259:16	fall	101:1, 5, 9	274:17		14 77:11
eye	314:1	116:20 121:1	finally	72:16	80:18 82:19
123:6, 11	383:6	124:3, 3 141:3,	find	20:20	93:6 97:21
eyes	familiar	4 252:10, 11	22:5	56:19	106:11, 15
	72:17 73:3	253:8 274:19	62:18	105:21	107:15 111:16
< F >	225:16 230:24	275:15, 20	106:17	138:18	113:22 129:7,
facing	261:16 298:14	276:2, 15, 19,	140:8	144:15	10, 18 138:18
37:8	305:3 322:15	21 277:18	159:22, 23		147:11 152:13
fact	323:8	278:22 279:1,	173:8	238:21	163:9 184:13,
34:7 61:5	familiarity	12, 23 280:1,	239:22	272:10	15, 20 190:7
65:8, 14 66:21	59:23	12 366:9	295:19	298:16	202:13, 15
78:12 117:11	family	February	325:4	356:17	203:7 213:6,
121:24 122:21	180:22	1:7	363:7	366:3	13, 14 216:21
146:18 152:24	188:23 189:13,	Fecal	122:2	144:12	224:22 254:20
156:24 166:22	15, 23	362:20,	145:6	233:22	263:10 267:11
167:7 173:24	famous	24 363:16, 17	238:12	274:3	273:20 297:17
178:18 181:20	375:20	feces	372:1		312:18 313:7
184:24 189:4	far	361:5, 7	findings		315:4 319:4
195:8, 9 203:9	42:23	Federally	320:23	325:24	320:23
220:4 222:9,	66:21 202:18	1:18	123:19	214:20	330:12 334:16
246:10 248:21	220:4 222:9,	Feeling	215:21	255:8,	339:13 340:15
251:6 261:24	239:22 265:10	204:12	12	267:17	350:16, 17
270:7, 9	325:6 381:6	fat	278:9	369:4	358:17, 24
284:17 323:13	fashion	117:14	finds	143:2	359:24 364:22
324:7, 23	204:12	303:10	fine	46:6, 23	371:1 381:7,
326:10 328:24	119:6, 14	feels	76:23	92:18	11
329:22, 24	fatal	169:15	104:3, 13	fit	113:21
334:5 341:22	284:16	Feldman	106:1	107:13	184:12 313:22
342:6 343:23	fate	80:19 84:5	120:3	130:15	fits
344:2, 18	119:1	323:15 324:5,	139:6	169:15	137:11
362:18 371:4	fax	6 332:13, 18	198:16	208:5,	334:16
373:7, 19, 22	12:15	334:1	18	238:5	fivefold
377:11 379:14	161:12 162:6	felt	249:14	253:22	159:4,
factor	228:2, 4, 18	87:8	339:1	364:9	11
250:23	229:19 298:22	198:6 293:15	finish	67:17	five-minute
254:13	299:12 303:4,	304:7	94:21	207:17	254:2
factors	9 304:4	female	101:23	106:24	flag
68:21, 24	356:15, 19, 20,	345:17	130:17	137:8	flaw
73:10 225:4	21 357:4	347:1, 19			Floor
334:21 337:14,	359:4, 7	fences			2:3
21 338:9	FDA's	239:16			
faculty	228:14	fewer			
58:24	feature	239:22			
failed	116:22,	fibrillation			
215:4	23 117:1, 2	322:10 327:6,			
	120:9 124:14	8			

Protected Information - Benjamin Lebwohl, M.D., M.S.

Florham 2:18	forceful	foundation	182:16 184:20	149:20 163:16
florid 225:20	112:11, 16, 20	18:11 19:11	199:21 216:21	190:13 191:6
flower 270:10	fore 94:2	215:15 216:5	224:22 315:24	225:7 242:3
focus 59:10	306:12	217:11 233:16	319:4 339:13	270:3 272:21
143:13 146:13	forefront 98:6	236:3, 11	340:15	299:13, 24
359:20	foregoing	249:24 298:24	fully 90:10	327:23 354:9,
focused 17:8	385:17	299:4 342:21	106:23 215:9	16 357:2, 13
51:21 87:9	Forgive 369:11	360:12 380:15	355:21	381:6
268:18	form 16:5	382:18	function 30:19	generalize 95:3
Focusing	124:9 181:13,	foundational	functioning	generalized
36:15 144:6	24 226:14	297:19 300:3	32:4	315:6
275:11 313:10	302:7 305:12	foundations	further 46:1	generally
folks 129:2	324:7 343:4	357:11	76:16 94:4	26:15 147:12
141:4 189:13	370:20 371:17	four 113:20,	96:19 107:3	148:1 211:22
190:6, 8	373:5 374:23	22 130:20	113:5 150:11	240:9 251:23
191:10 193:6	379:11 380:15	163:23 164:2	182:8 200:11	277:16 327:5
201:16 214:1	381:2 382:18	273:10 278:3	218:17, 17	generate
266:5 274:21	formal 13:13	283:19 334:15	219:18 220:6	24:17, 18
275:14, 16	101:14 117:19	345:9	246:21 251:11	25:11 36:19
276:12 277:15	187:14 188:3	fourth 273:15	338:1 344:18	92:11 164:15
285:24 350:7	196:4, 21	frankly 63:21	future 116:13	316:17 328:17
follow 103:20	356:13	120:10 148:13	146:13	354:12 355:17
104:5 105:17	formally 27:10	196:7 197:1	generated	
151:12, 22	forming 378:9	284:15 357:6	16:1 25:12	
186:17 353:9	formulate	fraught 149:4	gain 127:20	34:21 93:2
374:5	77:12	189:19	game 68:15, 16	95:22 98:20
followed 24:24	formulating	FREEMAN	gastroenteritis	137:5 310:3
25:1 151:8	91:19 317:2	2:1	69:6	357:8 367:12
180:1 251:24	forth 19:8	frequent	gastroenterolog	generates
314:6, 17	21:15 37:1	58:10 178:19	ist 58:4, 5	301:4
356:3	48:1 62:1	363:1	368:15	generating
following	87:14 170:12	frequently	25:10 40:14,	25:10
110:24 283:14	186:8 209:18	58:8 191:19	20, 24 41:9	40:14
284:8 383:5	250:3 267:11	241:14 304:20	42:1, 7 45:13	42:1
follow-on 78:9	270:1, 11, 14	314:24	93:9 163:20	45:13
268:2	282:21 293:6	friendly	generation	136:17
follows 9:9	332:19	305:18	40:17 41:19	40:17
173:14	forthcoming	front 36:4	164:17	164:17
follow-up	41:18	38:8, 24 40:3	generic 148:3	
151:5 167:3	fortunate	83:23 88:23	149:9 150:3	
173:20 179:18,	151:5	103:7 105:13	211:14 242:6	
23 206:23	forward 140:2	179:14 256:6,	325:18 373:20	
218:21, 21	found 56:12	17 262:24	Generically	
220:14 281:23	87:2, 7 88:4	272:24 291:18	354:4	
287:2 321:19	99:15 120:22	307:17 327:14	354:4	
377:12, 19	145:21 157:4,	340:13 357:3	gender 269:21	
378:2	23 200:5	frustrated	General 3:2	
Fonseka	214:7 239:17	304:5	4:24 28:5	
133:20 154:13	240:11 247:21	fuel 316:4	32:13 34:14	
foolish 252:24	261:8, 21	full 20:19	39:10 44:2, 3,	
	277:19 288:2	147:11 180:16	11, 24 78:21	
			134:16 148:22	119:24 120:12
				167:22 185:23

Protected Information - Benjamin Lebwohl, M.D., M.S.

193:4 195:2, 8	255:10 290:8	157:20 188:6	Greywoode	150:15 308:21
248:4 290:21	296:18 343:22	192:18 196:9	6:3 140:18	347:6
357:5	361:23	199:3 208:12,	145:4 146:2, 3	handed 12:18
GI 114:23	gluten-containi	13, 19 219:3	156:9, 10, 13,	28:15 34:18
141:12, 14	ng 78:15	248:10 250:16	15, 17, 18	179:6
143:9 190:6	gluten-free	252:3 255:17	236:21, 23	handful 344:14
315:1, 3, 6	167:22 168:21	271:3 277:22	237:21 238:15	handing
325:18	211:13 212:7	302:19 306:20	262:12, 20	320:10 335:17
give 17:19, 21	281:2, 5, 10, 14	307:3 324:14	263:2 371:22	handled
30:6 80:8	290:10	326:16 327:11,	378:23	372:14
96:8 106:16	gluten-induced	12 338:21	group 115:3	handy 305:18
107:5 132:13	168:13 169:7	343:23 345:20	129:1 145:23	Hang 321:7
134:13 190:10,	go 26:4 46:21	346:17 353:6	178:18 183:11,	haplotype
22 196:2	73:14 78:18	357:20 358:15	15 201:23	211:18
203:4 219:4	79:24 81:19,	366:13 372:8,	202:13 203:21	happen 49:14
272:9 283:10	23 86:13	15 383:4, 7, 11	204:20 220:22	68:6 315:7
319:22 321:1	93:17 94:16,	gold 148:9	240:9 246:14	351:8 363:24
330:15, 22	20 105:22	GOLKOW	249:1, 2 267:6	happened
332:10 334:24	106:6 107:14	1:22	273:3, 6, 9, 12,	246:4, 17
341:4 348:5	108:4 115:18	Good 9:14, 15	14, 15 274:10	281:23 282:4,
372:23	118:10 132:20	39:16 105:3	275:7, 9, 24	10, 18 308:15
given 64:1	137:9 139:15	140:1, 4	276:6, 22	315:3 338:15
103:6 113:3,	160:20 178:4	195:23 262:8	381:15	351:16 381:6,
17 199:23	182:14 207:21	264:17 294:5	groups 184:1	11
200:1 210:22	208:4 212:21	301:22 382:4	244:23 247:3	happening
222:14 249:4	214:21 236:15	gotta 79:23	249:6, 10	230:10
269:2 281:1,	255:16 259:1	318:14, 16, 19	273:10 274:23	happens 69:7
12 295:17	266:12 268:13	gotten 195:14	grow 168:24	235:19 247:19
298:12 311:11	277:23 292:17	gradient	guess 78:8	314:24
356:17, 20	303:11 304:14	224:15	121:23 199:20	happy 64:19
362:16 363:3	305:8 316:23	gradually	235:18 334:14	hard 175:19
364:16, 22	319:10 325:12	285:12	368:1 383:20	280:6
372:5 381:21	336:8 339:1	granted 95:6	Gujral 98:17	harder 251:15
385:6	353:15 361:1	99:11 108:7	gut 69:3	hard-pressed
gives 139:7	370:15, 24	132:8 138:21	127:15	171:7
glad 163:13	372:15 376:8	139:1	harmed 60:7	Hartranft
353:8	goal 342:5	granting 25:21	< H >	138:9 155:17
glancing 272:7	goes 75:2	grave 151:9	habit 361:9,	Hasebe 6:19
glean 242:22	159:2 167:23	great 73:4	10, 11	81:6, 8 334:17
gleaned 151:18	362:7 364:7	118:16 145:12	half 70:15	335:13, 20
global 334:17	369:1, 13	363:10	223:18	337:20 338:1
globally	going 13:17	Green 57:7	half-life 176:2,	Hasebe's
349:10	17:6 18:16	109:13 110:5	21 294:23	336:23
gluten 68:1, 5,	26:10 28:4	153:11 184:21	Haller 233:3	hat 357:4
10 73:11	32:16 33:10	187:7, 23	halted 230:16	HCT 191:23
78:22 79:5, 5	45:24 49:14	198:2 202:16	Hammoudi	341:2
168:6, 11, 15	72:13 83:22	204:2 214:19	137:24 155:13,	head 10:12
169:2, 14	86:13 105:12,	215:3, 20, 24	14	188:18 190:12
176:14, 16	19, 20 106:10,	263:4 271:5	hand 28:3	334:17 366:4
180:22 189:9	22 126:13	349:2, 23	48:8 149:12	
197:7, 9, 16	139:16 140:2			

Protected Information - Benjamin Lebwohl, M.D., M.S.

heading	190:10 197:7	280:10 291:11, 22 292:2	Ho's 308:6, 11, 13	259:3, 21 260:8
182:15 226:17	285:17	histology 6:5	hospitalization	identification
227:4 297:13	hesitate 188:17	53:7 109:24	116:3 285:8	9:5 14:14
headlined	hesitates	237:12 271:9	334:23	28:12 34:15
138:22	268:10	290:13 292:6		36:1 38:5
heads 129:15	Hey 39:18	histopathologic	hospitalizations	88:20 179:3
188:1	Hideki 81:12	88:8	293:18 337:16	201:2 256:3
heal 375:12	84:11	hierarchy	382:1	262:21 271:14
healing 183:5		histopathologic	hospitalized	307:13 320:7
296:14, 20	147:13, 20	al 87:6	284:6 285:7	335:14 340:6
375:10	148:1, 2, 3, 5,	253:14 273:24	hour 43:21	346:7 358:2
Health 59:2	13, 22 149:10,	274:3	372:15	identified
161:12 162:9	16, 21, 23	history 180:23	huge 239:13	15:19 19:6
164:6	150:3 372:18	188:23 189:13,	268:24 269:16	79:15 83:16
healthcare	high 285:11,	15, 23 193:17	human 60:6	84:10, 21
151:10 171:13	12 351:4	257:23 283:19	259:16	86:19 90:14
hear 311:22	374:3	322:10 326:11	humans 59:19	92:5 237:22
324:23	higher 114:15	HLA-DQ2	hundred	255:9 288:9
heard 185:15,	221:18 223:2	211:18	157:18 191:5	350:17
19 196:22	224:3 229:14	Ho 81:24	hung 119:24	identifies
303:8	high-impact	86:3 307:20	Hutless 164:3	91:11
hearing 184:21	370:1	308:22 309:1	hydrochlorothi	identify 58:3
heart 101:6, 8,	highly 154:11	333:8	azide 191:22	80:15, 19, 22
10		hoc 62:10	hypermotility	81:12 84:4
height 123:24	high-reputation	374:13	363:18	86:9 96:6
HeLa 261:16	370:2	hold 174:6	hypotension	105:5 106:11
held 1:15	Hill 224:16, 18,	233:19	284:7	107:2 113:19
help 45:19	24 225:5, 9, 17,	holiday	hypothesis	114:1 136:24
163:13 198:7	21, 23 226:4, 6,	287:22 288:5,	145:7, 18	152:6 161:10
212:24	17, 20 227:1, 9	8, 9, 10, 19	270:15	163:14 225:14
helped 272:14	241:9, 13	289:7, 19, 22	hypothesized	226:9 282:22
382:24	254:11 378:6	292:11, 12, 16,	66:9	283:5, 6 287:1
helpful 60:2, 3	Hinman 80:22	24, 24 293:9	hypothetical	319:5 338:10
87:7 88:6	81:5 85:24	294:8, 21	70:11	354:14, 24
91:21, 23 98:2	hint 98:2	295:15, 15		355:9, 12
119:18 152:4	histologic 50:7,	330:7, 24	<I>	360:7 370:17,
242:12 261:21	19, 21 51:10	331:4, 11, 16,	i.e 192:24	23
266:11 290:6	53:23 54:3	23 332:11	332:8	identifying
297:20 300:4	69:23 74:3, 5	holidays	iceberg 143:19	372:21
302:15 356:1	96:17 111:2	288:14	239:9 360:8,	ill 142:1
364:12 373:2,	153:13 167:12	homogeneous	15 363:7	166:17 169:3,
12, 19 382:14	168:1 192:20	129:17, 17	idea 61:11	4 183:1
383:16	255:12 257:5	honest 171:11	208:15 267:8	195:11, 16
hero 164:6	290:4, 22	honestly 25:19	ideal 100:23	255:10 284:18,
herring 328:1	291:1, 5	54:19 122:12	260:10	22 327:3
Herve 81:16	histological	hoops 199:6	ideally 304:7	ill-defined
86:6 353:21	74:3 100:19	hope 26:6	ideas 91:22	124:17
hesitant	255:8 296:5	265:21	identical	illness 285:5
121:17 124:18	Histologically	hopefully	194:8 221:3	288:21 296:6
142:1 144:18	74:8 245:19	301:5		323:19 324:2

Protected Information - Benjamin Lebwohl, M.D., M.S.

325:16 332:15	implicitly	295:3 296:21	11 247:6	indication
334:7	318:2	369:5 375:24	248:14 257:14	265:11 325:14
illustrated	implied	376:5, 19	313:22 348:15	327:16 331:3
288:11	132:23 133:10,	377:6	inclusive	indirectly
illustrative	16, 17, 18	improvements	247:13 360:22	306:18
99:7 287:20	imply 139:2, 2,	187:2	incomplete	individual
345:3	10	160:17 181:10,	80:6 309:21	70:2, 4, 24
imagine 142:5,	implying 282:7	17	314:9	71:6, 14 120:5
17 169:11	import 139:12	inaccurate	inconsistent	149:4, 8 223:8,
301:1, 6	importance	272:9	313:12	10 302:1
imaging 97:18	149:17	inadequately	incontinence	individuals
immediate	important	101:18	362:20	62:22 63:4, 12
16:20	241:11 259:23	inadvertent	incorporate	69:13, 19, 21
immediately	292:1 301:11,	163:9	306:16	70:7 73:13
21:11 344:5,	15 302:3	incidence 64:3	incorporates	108:17 117:9
20	343:16 352:15,	270:6 353:3	369:22	120:23 157:23
immune 67:5	19 360:11	incident 71:1	increase	163:23 178:14
69:4 259:11	364:15 365:4	include 15:18	159:11 224:2	260:6
Immunopathog	372:3	16:17 17:16	increased	individual's
enesis 5:18	imposed	36:23 154:22	93:20 159:4	375:11
135:14 154:20	281:15	184:7 247:11	224:2 363:16	induce 108:20
254:16 255:24	impractical	248:11 257:23	increasing	115:13 127:18
immunosuppres	151:17	304:21 364:7,	221:17	induce, 103:13
sant 193:16	impression	10 366:10	increasingly	induced
246:3	178:20 189:2	369:16, 24	61:6 64:3	116:12 138:8
immunosuppres	316:21 373:15	imprimatur	132:7	induces 50:20
sants 192:9,	234:4	375:11 383:7	INDEX 8:2	inducing 224:6
11 193:6	improve 78:5	included 75:3,	104:12	induction
194:13 205:23	183:11, 16, 18	4 77:23 78:2	indicate 10:2	67:13
206:2, 6, 19	215:4 216:2	79:9 85:1	59:13 146:10	infarction
248:24 249:5	improved	93:15 99:18	206:4 221:24	101:11
immunosuppres	182:21 200:4	186:10 206:7	274:17 278:14	infection 171:2
sion 193:2	202:4 206:20	225:23, 24	287:11, 16	infer 331:9
194:5 243:10,	221:8, 14	256:24 257:17	311:12 326:20	inflammation
21 245:7	245:18 283:14	298:21 300:13,	327:23 330:6	59:14 364:8
246:12, 19	293:15 377:20	14 353:2, 19	341:17 352:23	inflammatory
247:1, 4, 15	improvement	368:10 369:18	indicated	177:19
248:16, 19	111:2 167:24	includes 15:14	206:22 219:18	inform 185:24
immunosuppres	175:13 176:7	50:18 283:4	240:6 343:12	informal 204:7
sion's 250:6	177:1 193:19	287:8 335:21	351:11 376:21	INFORMATIO
immunosuppres	195:6, 22	336:4 369:3	indicates	N 1:7 88:7
sive 377:21	205:21 206:1,	including 24:5	61:21 146:16	91:12 110:17
impact 262:3	5, 10 209:2, 21	72:14 87:16	184:10 211:11,	199:23 200:1
impacted	210:7 216:9	89:10 91:13	15 218:18	242:12 297:20
157:11	218:14, 23	121:2 253:13	287:21 310:18	300:4 321:20,
implicated	220:11 243:18	305:14 349:19	330:1, 11, 13	24 329:16, 19,
325:20	247:14, 15	inclusion	334:8	21 330:1
implication	284:5 289:2,	77:19, 22	Indicating	380:1, 7, 9
284:15	23 290:12, 13,	128:9, 10	81:1 133:6	381:17 382:8
implications	17 293:11	183:15 184:12	220:8 347:12	informed
268:11		245:14 246:9,	376:12, 13	75:20 114:20

Protected Information - Benjamin Lebwohl, M.D., M.S.

infusion	73:1 199:1	internally	investigate	150:14 160:16
294:15	instruct 46:5	351:20 380:7	49:6 62:8, 13	199:8 243:15
ingredients	instructions	international	63:20 64:7	244:11 264:7,
192:1	9:22	116:10	169:5	23 285:13
initial 93:16	insufficiency	interobserver	investigated	306:10 360:23
106:9 110:9	383:14	125:5	50:2 53:23	362:11 370:5
122:5 133:5	insufficient	interpret 133:5	investigation	issued 11:4
178:20 183:20	123:17 126:8	interpretation	75:4 78:2	it, 377:22
185:16 212:21	intend 47:14,	128:21 159:5,	257:17, 18	item 133:23
233:22 247:11	24 48:10	6 183:14, 21,	investigations	163:6
248:11 314:2	intended	24 184:4	79:10	items 11:21
349:15	239:24 286:2	202:2 218:11	investigator	12:1 15:14, 18
initially 27:8	intentional	328:14	164:10	90:15 91:12
33:6 74:13, 20	342:6	interpreted	investigators	358:18, 19, 23
75:8, 14, 21	intentionally	125:11	115:4 244:23	iteration 36:17
93:2 104:9	342:1, 4	interprets	246:13 258:22	It'll 105:24
174:13 203:10	interacted	332:22	259:20 286:1	106:1
212:8, 17	58:15	interrupt	invite 161:17	its 53:12
213:18 214:5	interactions	175:4 207:3,	Invoice 4:21	96:20 98:13
224:23 228:24	58:10 304:17	16 342:22	28:10, 20 29:1	137:7 143:2
239:24 246:18	interchangeability	interval 158:5,	42:16 82:19,	146:17 228:5
365:14	212:11	14, 17 159:1, 7	23 83:7, 17, 21	251:13, 13
initiate 183:3	interchangeable	intervention	84:2, 9, 17	252:10 275:6
initiated	362:2	171:4, 19	85:5, 23	328:21 329:23
287:13 294:7		230:15	invoiced 85:1	356:16 364:18
initiating	interchangeably	interventions	Invoices 5:3	< J >
367:5	252:4	148:15	12:19, 21	January 53:12
initiation	interest 339:8	interviews	28:18 38:3, 11	97:23 332:2, 4
315:11	353:12 382:15	intestinal 50:7	39:2 40:5, 8,	Japan 334:18
initiative	383:4, 10	114:17 121:5	12, 18, 22 41:5,	Jeffrey 81:14
120:21	interested	134:6 231:12	17, 18 42:2	JERSEY 1:2
injured 127:15	32:22 144:1	233:4 262:7	82:17 83:11	2:4, 18
injury 23:19,	162:5 186:14	296:19 363:9,	85:19 86:5	JESSICA 2:17
24 119:4	218:1 238:7	11 364:9	involved 24:23	jessica.brennan
input 13:16	267:4	368:23	25:22 56:13	@dbr.com
357:9	interesting	intestinal-relate	167:10 202:22	2:19
inputs 317:6	74:17	d 231:6, 17	203:16, 20	Joe 187:24
inside 129:15	intermittent	233:13	236:1 284:18	jogged 98:10
356:19	128:20 327:7	intestine 59:15	involves	joke 292:17
instance	intermittently	123:5 261:8	167:13, 15	journal 18:5
132:20 141:21	71:11	262:2, 4	257:22	53:11 57:9
174:8 222:3	Internal	intimately 21:1	involving 27:7	136:16 154:12
288:8 303:19	107:17 136:6	introduce	370:6	370:2, 3
333:8	297:13, 18	202:21	iron 119:9, 11	JS 1:6
instances	298:1, 6, 19	introduced	121:2	judgment
65:15, 20	299:7, 18	68:6 327:19	98:24	333:19
66:18, 20	300:2, 15	introduction	issue 26:16, 20,	Julian 93:19
168:3 170:20	368:17 370:4	108:22	21 50:24	July 161:13
354:14	374:18 379:23	invariable	63:16 98:23	339:16 340:23
institution	380:9, 18, 22	165:10	114:6 149:11	jump 208:14

Protected Information - Benjamin Lebwohl, M.D., M.S.

jumping	164:7 269:18	known	123:23	largest	276:20	Lebwohl-13
323:10	330:2 344:3	164:5 191:19	277:12	6:8 307:9		
jury	76:18, 19	know	204:4 223:8,	lasted	288:14	Lebwohl-14
jury's	76:14	14:23 18:20	15 252:21	lasting	218:23	6:12 320:3
		26:15 39:7	325:15 333:11	late	37:9, 10	Lebwohl-15
< K >		46:12 49:12	382:2	42:8, 13 44:9	42:8, 13 44:9	6:16 335:11
Kaplan	1:16	54:12 55:4		72:3		Lebwohl-16
2:7	64:2, 18 66:21			latency	229:10	6:19 339:24
KATZ	2:1	67:18 68:23	label	226:19	laugh	Lebwohl-17
keenly	186:16	70:10 71:22	211:22	226:6	7:3 346:1	
keep	10:11, 16	73:7 77:15	labeled	212:17	law	1:15
140:2 187:13	82:3 96:2	213:18 214:6		LAWYER'S		Lebwohl-18
188:12 317:19	118:5 119:6, 7		386:1	386:1	7:7 358:1	
363:8	121:20 125:21	laboratory	lay 352:11			Lebwohl-2
keeping	127:14, 19	69:23 253:15	layer 278:18	4:16 14:9		
187:14 188:2	144:7 145:15,	290:4	lead	120:15		Lebwohl-3
195:1 363:22	20 147:5	lack	315:18 353:9	4:21 28:10		
Ken	9:16	64:24	leads 221:18	4:21 34:12		
207:15	150:24 157:19	177:21 215:14	224:3	Lebwohl-4	4:21 34:12	
KENNETH	158:6 169:22	216:4, 8	224:3	4:21 34:12	5:1	
2:12	181:19 182:5	217:10 233:15	learn 202:7	4:21 34:12	35:23	
kenneth.murph	188:16 190:18,	236:2, 10	270:4	Lebwohl-5	5:1	
y@dbr.com	20, 22 192:3, 5	249:23 251:15	learned	4:21 34:12	38:2	
2:15	194:2 196:18,	298:23 299:3	17:4	Lebwohl-6	5:1	
kept	23 204:8	377:12 378:2	21:3 123:4	38:2	5:1	
188:21	207:19 208:11,	380:15 382:18	202:20	Lebwohl-7	5:5	
KESSLER	13 213:21	lacks	learning	88:15		
164:3, 5	218:1 222:11	110:16	64:3			
Kessler's	239:6, 10, 12	Lagana	leave 329:11	Lebwohl-8		
102:15, 17	102:15, 17	6:8	LEBWOHL	5:10 178:24		
Kim	257:10, 13	53:3, 17 86:10	1:15 4:5, 14,	Lebwohl-9		
48:20	258:14, 23	96:14 102:4	19, 21, 23 5:4,	5:12 200:21		
54:10 66:11	259:10 269:2,	110:3 112:18	9 9:4, 7, 14	Lebwohl's		
173:9 207:22	16, 24 279:5	131:18 153:5,	10:22 14:12	13:2		
312:5	288:18, 23	9, 10 237:2, 21	15:4 18:1	Leffler	102:6	
Kimberly	291:13 295:18	238:6 271:3,	22:19 28:11,	164:9, 17		
385:13	296:4 312:2	13, 20	15 34:13 38:3	Leffler's		
kind	317:22 326:18	Lagana's	48:10 59:12	102:20		
10:14	18:15 25:6	86:20 87:3, 13,	61:20 88:19	left	132:11	
159:10 223:5	327:2 343:1	17, 17, 22 88:5	89:2 103:8	163:9 182:14		
232:15 245:21	344:9 347:2	89:12 102:21	108:23 109:13	303:10 304:10		
257:21 265:14	352:5, 7	laid	110:5 112:19	356:5 365:9		
269:11, 14	353:12 357:1	370:6	131:15 153:10	legal	12:9	
285:3 325:7	362:16 364:16	land	164:24 198:23	26:3 77:1		
326:10 345:3	372:8 381:9	230:11	333:3 358:7	legitimate	26:2	
354:17 360:18	382:11	language	385:8	legs	254:5	
kindly	knowing	111:14 370:5	Lebwohl-1	lends	251:11	
270:17	189:22	60:5 120:23	4:12 9:3	length	132:2	
kinds	knowledge	239:17 242:23	Lebwohl-10	331:16, 21		
359:23	15 262:2	244:14 261:8,	5:18 255:23	lesions	138:3	
kitchens	63:18 64:24	301:2	Lebwohl-11	lesser	93:21	
197:11	95:5, 8 99:12	largely	5:22 262:15	122:8		
Klug	162:4 177:22	87:2	Lebwohl-12	Lethargic		
knew	224:10 231:11	202:1	6:4 271:8	126:5, 7, 9		
73:2 97:15	352:1, 9	larger				